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1. Introduction 
This report summarises results from the 
thirteenth proficiency test trial conducted by the 
National Food Institute (DTU Food) as the EU 
Reference Laboratory for Antimicrobial 
Resistance (EURL-AR). This proficiency test 
focuses on Salmonella and Campylobacter and 
is the seventh External Quality Assurance 
System (EQAS) conducted for these 
microorganisms (the first was EQAS 2006). In 
addition, the proficiency test for the fourth time 
includes an optional element consisting of 
genotypic characterization by PCR/sequencing 
of antimicrobial resistance genes. This optional 
component included characterization of genes 
related to production of extended spectrum 
beta-lactamases (ESBL) in the ESBL-producing 
Salmonella test strains. 
The objective of the EQAS is to monitor the 
quality of the antimicrobial susceptibility data 
produced by the NRL-AR and to identify areas 
or laboratories, for which guidance or 
assistance would be required as means of 
producing reliable susceptibility data. The goal 
until the 2008 iteration was to have all 
laboratories performing antimicrobial 
susceptibility testing (AST) with less than 7% 
incorrect interpretations. This was reconsidered 
at the EURL-AR workshop 2009, and as of the 
2009 iterations, the goal is to have each 
laboratory performing AST with less than 5% 
incorrect interpretations (interpretations 
deviating from the expected results). For the 
optional genotypic characterisation, no specific 
acceptance level has been set. 
The data in this report are presented with 
laboratory codes. A laboratory code is known to 
the individual laboratory whereas the entire list 
of laboratories and their codes is confidential 
and known only to the EURL-AR and the EU 
Commission. All conclusions are public. 
The technical advisory group for the EURL-AR 
EQAS scheme consists of competent 
representatives from all National Reference 
Laboratories for Antimicrobial Resistance 
(NRLs), who meet annually at the EURL-AR 
workshop. 
The AST data reported to EFSA by the Member 
States (MS) is based on the interpretation of the 
AST results. The basis for this EQAS evaluation 
is the interpretation of the AST result; as is also 
stated in the protocol, the “main objective of this 
EQAS is to assess and improve the 
comparability of surveillance and antimicrobial 
susceptibility data reported to EFSA by the 
different NRLs”. In addition, the participants of 
an EQAS should evaluate their own results and 
introduce corrective actions if necessary. The 
categorization of an uploaded interpretation as 
incorrect in the EURL-AR EQAS should induce 
the participant to perform a self-evaluation. This 
self-evaluation could very well include a 
comment on the fact that an acceptable 
deviation for MIC‐determination is ± one dilution 
step, which in some cases may affect the 
interpretation of the result. Therefore, the self-
evaluation may lead to arguments which can 
defend the obtained results internally, yet, 
incorrect interpretations based on a one step 
dilution difference are still regarded as a 
deviation for the overall EQAS reporting, 
evaluation and is kept as such in the database. 
The EURL-AR is accredited by DANAK 
(accreditation no. 516) as provider of 
proficiency test for zoonotic pathogens and 
indicator organisms in bacterial isolates 
(serotyping, identification, and antimicrobial 
susceptibility testing). 
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2. Materials and Methods  
2.1 Participants in EQAS 2012 
A pre-notification (App. 1) of the EURL-AR 
EQAS on AST of Salmonella and 
Campylobacter was distributed on the 16th July 
2012 by e-mail to the 41 NRLs in the EURL-AR-
network including all EU countries (except 
Luxembourg where no NRL has been 
designated) and including Croatia, Iceland, 
Norway, Serbia and Switzerland. One 
laboratory did not participate as they had 
neither Salmonella nor Campylobacter AST as 
their field of responsibility. In addition, Iceland 
and Serbia did not participate in this iteration. In 
addition to the AST of Salmonella and 
Campylobacter, an optional genotypic 
characterization by PCR/sequencing of 
antimicrobial resistance genes of the ESBL-
producing Salmonella test strains was offered.  
Appendix 2 shows that 32 of the 38 
participating NRLs were appointed by the 
individual Member States. Two NRLs were 
enrolled on equal terms as the designated 
NRLs, based on their participation in an EU 
funded concerned action (FAIR5-QLK2-2002-
01146), the ARBAO II project (Antibiotic 
Resistance in Bacteria of Animal Origin). The 
laboratories in Croatia, Norway, Switzerland 
and Turkey were charged a fee for their 
participation in the EQAS, whereas the NRLs 
from EU Member States participated free of 
charge. 
 
Figure 1: Participating countries that performed antimicrobial susceptibility testing of Salmonella or both 
Salmonella and Campylobacter.  
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Figure 1 illustrates that of the 30 participating 
countries, 27 tested both Salmonella and 
Campylobacter. Three countries, for various 
reasons, uploaded Salmonella results, only, for 
evaluation (Croatia, Greece and Turkey). 
Eleven laboratories  participated in the optional 
genotypic characterisation of the ESBL-
producing Salmonella test strains (not 
illustrated in Figure 1; see Appendix 2).  
The results from the NRLs designated by the 
MS are presented and evaluated in this report 
in addition to national reference laboratories in 
affiliated non-MS; i.e. results from 30 countries 
consisting of 35 laboratories submitting 
Salmonella results and 29 laboratories 
submitting Campylobacter results. Results from 
the two laboratories not designated by the MS 
but enrolled on equal terms as these are not 
further presented or evaluated in this report. 
2.2 Strains  
Eight Salmonella strains and eight 
Campylobacter strains were selected for this 
trial among isolates from the strain collection at 
DTU Food. Individual sets of the Salmonella 
strains were provided as agar stab cultures and 
the Campylobacter strains as charcoal swabs in 
transport media (Stuarts). 
The shipment of strains included the lyophilised 
international reference strains for antimicrobial 
susceptibility testing; Escherichia coli CCM 
3954 (ATCC 25922) and Campylobacter jejuni 
CCM 6214 (ATCC 33560) purchased at Czech 
Collection of Micro-organisms (CCM), the 
Czech Republic for the NRLs which had not 
received these reference strains in previous 
EQAS’s conducted by DTU Food. 
Prior to distribution of the strains, AST was 
performed on the Salmonella and 
Campylobacter strains at DTU Food and 
verified by the US Food and Drug 
Administration (FDA). When MIC-values were 
not in agreement (+/- one MIC-step), the value 
obtained by DTU Food was selected as the 
reference value. The obtained MIC values 
served as reference for the test strains (App. 3a 
and 3b). Results from the following 
antimicrobials were not verified by FDA: 
cefotaxime, cefotaxime/clavulanic acid, 
ceftazidime, ceftazidime/clavulanic acid, 
imipenem, imipenem/EDTA, and trimethoprim 
for Salmonella and furthermore, 
chloramphenicol and streptomycin for 
Campylobacter. 
2.3 Antimicrobials  
The antimicrobials tested in this EQAS are 
listed in the protocol (App. 4b) and were 
included mainly according to the 
recommendations of the European Food Safety 
Authority (EFSA) monitoring programme 
[Report of the Task Force of Zoonoses Data 
Collection including a proposal for a 
harmonized monitoring scheme of antimicrobial 
resistance in Salmonella in fowl (Gallus gallus), 
turkeys, and pigs and Campylobacter jejuni and 
C. coli in broilers, the EFSA Journal (2007), 
96,1-46]. A few additional antimicrobials have 
been added as indicated in the protocol due to 
the included element on detection of ESBL 
production. 
The selection of antimicrobials used in the trial 
for Salmonella were: ampicillin (AMP), 
cefotaxime (CTX), cefotaxime/clavulanic acid 
(CTX/Cl), ceftazidime (CAZ), 
ceftazidime/clavulanic acid (CAZ/Cl), ceftiofur 
(XNL), chloramphenicol (CHL), ciprofloxacin 
(CIP), gentamicin (GEN), nalidixic acid (NAL), 
sulfonamides (sulfamethoxazole) (SMX), 
tetracycline (TET) and trimethoprim (TMP). 
Additionally, cefoxitin (FOX) was used for 
detection of ampC, and imipenem (IMI), 
imipenem/EDTA for detection of metallo-beta-
lactamases (MBL). 
Minimum Inhibitory Concentration (MIC) 
determination of the Salmonella test strains was 
performed using the Sensititre system from 
Trek Diagnostic Systems Ltd, UK. For ESBL 
confirmatory test, the analysis included MIC 
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determination by microbroth dilution (panel 
code ESB1F), and in addition, for the 
antimicrobials cefotaxime/clavulanic acid, 
cefoxitin, ceftazidime/clavulanic acid, tests were 
performed using E-test from AB-Biodisk, 
Sweden. The method guidelines used were 
according to the Clinical and Laboratory 
Standards Institute (CLSI) document M7-A9 
(2012), “Methods for Dilution Antimicrobial 
Susceptibility Tests for Bacteria That Grow 
Aerobically” (Approved Standard - Ninth 
Edition), document M100-S22 (2012) 
“Performance Standards for Antimicrobial 
Susceptibility Testing” (Twenty-Second 
Informational Supplement) and document M31-
A3 (2008) “Performance Standards for 
Antimicrobial Disk and Dilution Susceptibility 
Tests for Bacterial Isolated From Animals” 
(Approved Standard – Third Edition). 
For Campylobacter the following antimicrobials 
were included: chloramphenicol (CHL), 
ciprofloxacin (CIP), erythromycin (ERY), 
gentamicin (GEN), nalidixic acid (NAL), 
streptomycin (STR), and tetracycline (TET). 
MIC determination was performed using the 
Sensititre systems from Trek Diagnostic 
Systems Ltd, UK, according to guidelines from 
the CLSI document M45-A2 (2010) “Methods 
for Antimicrobial Dilution and Disk Susceptibility 
Testing of Infrequently Isolated or Fastidious 
Bacteria” (Approved Guideline – Second 
Edition) and M31-A3 (2008) “Performance 
Standards for Antimicrobial Disk and Dilution 
Susceptibility Tests for Bacterial Isolated From 
Animals” (Approved Standard – Third Edition). 
2.4 Distribution 
On October 1st, 2012, the cultures and a 
welcome letter (App. 4a) were dispatched in 
double pack containers (class UN 6.2) to the 
participating laboratories as UN3373, biological 
substance category B, according to the 
International Air Transport Association (IATA) 
regulations.  
2.5 Procedure 
Through the EURL-AR website, http://www.eurl-
ar.eu/, the laboratories were provided with 
protocols and information regarding the 
handling of the test strains and reference 
strains (App. 4b, c, d, e). The participants were 
instructed to subculture the strains according to 
the description in the protocol prior to 
performing the AST. Furthermore, participants 
receiving an ATCC reference strain were 
requested to save and maintain this for future 
proficiency tests. 
The aim is that only MIC methods are used 
when performing AST for monitoring conducted 
by the Commission, and thereby also when 
performing the EURL-AR EQAS’s. 
Consequently, it was decided in May 2007 by 
the participants at the EURL-AR workshop that 
the NRLs should work towards harmonising to 
MIC methods for these AST analyses. 
Additionally, it was agreed that all NRLs should 
work towards covering the antimicrobial panel 
and epidemiological cut-off values 
recommended by the EURL-AR. For this 
EQAS, the participants were instructed to use 
as many as possible of the antimicrobials listed, 
using the method carried out when performing 
monitoring for EFSA. 
The cut-off values recommended by EFSA 
should be used (listed in the protocol). All cut-
off values used in the interpretation of the 
Campylobacter MIC results have been 
developed by EUCAST (www.eucast.org). This 
is also the case for Salmonella with the 
exception of sulphonamides, where the value 
from CLSI was used according to the 
description in the protocol (App. 4b).  
Participants using disk diffusion (DD) or E-test 
were recommended to interpret their results 
according to their individual routine, 
categorising the test strains into the terms 
resistant and susceptible. A categorisation as 
‘intermediate’ was not accepted. The 
breakpoints used were submitted to the web 
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based database. Breakpoints applied for disk 
diffusion for Salmonella are listed in Appendix 
5.  
It should be noted that for AST of 
Campylobacter the EURL-AR does not 
recommend the use of either disk diffusion or E-
test for AST of Campylobacter. I.e. only results 
obtained by broth or agar dilution methods are 
accepted for this EQAS, as also agreed at the 
EURL-AR workshop 2009.  
The laboratories were instructed to upload 
obtained MIC values (mg/L) or inhibition zone 
diameters (mm) and the susceptibility 
categories (resistant or susceptible) to the 
database through a secured individual login. 
Alternatively, the record sheets from the 
protocol could be sent by fax to DTU Food. The 
website was open for data entry in the period 
from the 25th of October 2012 to the 22nd of 
December 2012. 
Detection of ESBL-producing strains should be 
performed and interpreted according to 
recommendations by EUCAST described in the 
protocol. Concerning the cephalosporins used 
when detecting ESBL-producing strains, MIC 
values and interpretations of these should be 
reported as found.  
Results from the reference strains should also 
be entered into the database. The results would 
consist of MIC values for the reference strains 
E. coli (ATCC 25922) and C. jejuni (ATCC 
33560) or, for E. coli (ATCC 25922), the 
inhibition zone diameters in millimetres. The 
results should be in agreement with the quality 
control ranges according to the relevant 
guidelines; i.e. the CLSI documents M31-A3 
(2008) or M100-S22 (2012); The Sensititre 
System (Trek Diagnostic Systems Ltd, UK) 
(App. 7). 
For the optional genotypic characterisation of 
the ESBL-producing Salmonella test strains, 
participating laboratories were requested to 
report the genes conferring resistance to 
extended-spectrum beta lactam antimicrobials. 
The genes listed in the table in the protocol 
(App. 4b) were included in the test. 
Identification of additional genes not listed in 
the protocol was not evaluated by the database. 
The results were evaluated based on the actual 
genes identified. Relevant variants of ESBL-
genes were additionally evaluated.  
The participating laboratories were encouraged 
to use their own laboratory’s method(s) for the 
genotypic characterisation. The expected 
results for this component of the EQAS were 
obtained by whole-genome-sequencing and 
subsequent analysis using the ResFinder 1.3 
platform available at 
http://cge.cbs.dtu.dk/services/ResFinder/. The 
positive identifications of genes was not verified 
elsewhere. 
Subsequent to the submission deadline, the 
laboratories were instructed to login to the 
secured database once again to retrieve the 
database-generated, individual evaluation 
report. The evaluation included assessment of 
the submitted results and a description of all 
deviations from the expected. Deviations in the 
interpretation as resistant or susceptible were 
categorised as ‘incorrect’, as was also 
deviations concerning confirmation of an isolate 
as ESBL-producer or ampC.  
The EURL-AR is aware that there are two 
different types of interpretative criteria of 
results, clinical breakpoints and epidemiological 
cut-off values. The terms ‘susceptible’, 
‘intermediate’ and ‘resistant’ should be reserved 
for classifications made in relation to the 
therapeutic application of antimicrobial agents. 
When reporting data using epidemiological cut-
off values, bacteria should be reported as ‘wild-
type’ or ‘non-wild-type’ (Schwarz et al., 2010). 
Due to the different methods of AST used by 
the participants and also to simplify the 
interpretation of results, throughout this report, 
we will still maintain the terms susceptible and 
resistant, even in cases where we are referring 
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to wild-type and non-wild-type strains. 
The database included questions for evaluation 
of the EQAS as well as questions regarding the 
individual laboratories’ work in the area of AST. 
Few laboratories used these features for 
sending comments to the EURL-AR. When 
relevant, those who did received direct reply.  
3. Results 
The participants were asked to report results, 
including MIC values or inhibition zone 
diameters obtained by DD together with the 
categorisation as resistant or susceptible. Only 
the categorisation was evaluated, whereas the 
MIC values and disk diffusion inhibition zones 
were used as supplementary information. 
At the EURL-AR workshop 2008, the network 
agreed that if less than 75% of the results were 
correct, based on strain/antimicrobial 
combination, these results should be further 
analysed and possibly omitted from evaluation. 
In the present EQAS this occurred in one case: 
for the combination of the test strain C-
7.1/tetracycline with a level of agreement with 
the expected results at 71% (Appendix 8b 
presents the total number of correct/incorrect 
results for this strain/antimicrobial-combination).  
The expected MIC (2 mg/L, susceptible) was 
determined by two different institutions; DTU  
Figure 2: Distribution of the different MIC values 
obtained by participants for the combination C-
7.1/tetracycline. 
Food and FDA, and was within one fold dilution 
difference from the cut-off value (>2 mg/L).  
Figure 2 illustrates the distribution of the MIC 
values together with the interpretation of these 
values obtained by participants for the 
combination of strain C-7.1/tetracycline. The 
figure shows a distribution of MIC’s with the 
expected value at 2mg/L and a high number of 
participants obtaining AST results one MIC-
dilution higher than the expected result.  
Based on the facts that the precision of the 
method relies on various factors, including the 
media content the type of microbroth panels, 
and the fact that an MIC result obtained by the 
microbroth method or agar dilution can vary +/- 
one dilution step from the obtained MIC, this 
strain/antimicrobial combination has been 
excluded from the evaluation.  
3.1 Methods  
In the Salmonella trial, 30 laboratories used 
MIC determination (28 used microbroth and two 
agar dilution), and five laboratories used disk 
diffusion. For the Campylobacter trial, all 29 
included laboratories reported the use of MIC 
determination (microbroth or agar dilution).  
3.2 Deviations, overall 
The list of deviations is shown in Appendix 9a 
and 9b. Figure 3 shows the total percentage of 
deviations from the expected results of AST 
performed by participating laboratories. The 
internal control strain mainly followed the trend 
in deviation level of the different EQAS trials 
(Figure 3). The deviation level in 2012 is 
acceptable for both the Salmonella and the 
Campylobacter trials. 
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Figure 3: A comparison between the EURL-AR EQAS’s since 2006, showing the total percentage of deviations 
for antimicrobial susceptibility testing performed by participating laboratories.  
 
Figure 4: The total percentage of deviations for AST’s 
performed using MIC-methods as opposed to disk 
diffusion. 
3.2.1 Salmonella trial  
For the Salmonella strains, 99.0% of the AST’s 
were interpreted correctly. Figure 4 shows the 
total percentage of deviations from the 
expected results of AST performed by MIC-
methods as opposed to disk diffusion. The 
deviation percentage is significantly higher 
(p<0.01) when AST is performed by disk 
diffusion compared to a MIC-method.  
The number of AST’s performed and the 
percentage of correct results for the individual 
strains in the EQAS, are listed in Table 1. 
Variations of obtained correct results ranged 
from 97.4-100% for Salmonella. Table 2 
illustrates the percentage of correct AST per 
antimicrobial by bacterial species. The level of 
correct AST was above 97.4% for the 
Salmonella test strains. Ciprofloxacin exhibited 
the lowest deviation level.  
ESBL-producing Salmonella test strains 
It was decided on the EURL-AR workshop 2008 
that the testing of ESBL production in 
Salmonella should be mandatory. The 
laboratories were asked to detect the ESBL-
producing Salmonella strains and to perform 
confirmatory testing on all relevant strains 
resistant to cefotaxime (CTX), ceftazidime  
(CAZ) or ceftiofur (XNL) according to the 
protocol (App. 4b).  
The four test strains; S-7.1, S-7.2, S-7.3 and S-
7.6 were ESBL or ampC-producers, which was 
confirmed by the majority of the 35 laboratories  
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Table 1. The number of AST performed and the percentage of correct results for each strain of Salmonella and 
Campylobacter. 
EQAS 2012 – Salmonella  EQAS 2012 – Campylobacter 
Test strain AST in total % correct  Test strain AST in total % correct 
S-7.1 356 98,6  C-7.1 (C. coli) 168 98,2 
S-7.2 354 100  C-7.2 (C. coli) 196 98,5 
S-7.3 352 97,4  C-7.3 (C. coli) 197 98,0 
S-7.4 352 99,1  C-7.4 (C. coli) 197 95,9 
S-7.5 354 99,7  C-7.5 (C. jejuni) 196 97,4 
S-7.6 353 99,4  C-7.6 (C. jejuni) 197 99,0 
S-7.7 351 99,4  C-7.7 (C. jejuni) 197 98,5 
S-7.8 351 98,0  C-7.8 (C. jejuni) 197 97,5 
 
Table 2: Percentage of correct antimicrobial 
susceptibility tests per antimicrobial by 
microorganism. In grey, antimicrobials 
recommended in the EFSA zoonosis monitoring 
manual.  
Antimicrobial Salmonella Campylobacter 
Ampicillin 100.0 - 
Cefotaxime 99.3 - 
Ceftazidime 99.2 - 
Ceftiofur 98.8 - 
Chloramphenicol 99.3 100.0 
Ciprofloxacin 97.4 97.4 
Erythromycin - 97.0 
Gentamicin 99.3 100.0 
Nalidixic acid 98.9 96.5 
Streptomycin - 96.6 
Sulphonamides 97.9 - 
Tetracycline 99.6 98.0 
Trimethoprim 98.9 - 
participating in the Salmonella EQAS. Three of 
the ESBL-producing strains were so-called ‘true 
ESBLs’ (S-7.1, S-7.2 and S-7.3), and one was 
an ampC-producing strain (Table 3). As the 
ESBL detection part is mandatory in this EQAS, 
all results are evaluated below. 
There is a difference in the number of 
cephalosporins used by the laboratories in their 
routine test for ESBL production; five 
compounds are included in this proficiency test: 
cefotaxime, ceftazidime, ceftiofur, 
cefotaxime/clavulanic acid and 
ceftazidime/clavulanic acid. The first three are 
used for initial screening whereas the last two 
are used for confirmatory test (the combination 
disk method). The proportion of laboratories 
using different combinations of cephalosporins 
for screening for ESBL-production were nine 
laboratories using the combination CTX, CAZ, 
XNL, 21 laboratories using CTX, CAZ, one 
laboratory using CTX, XNL, and four 
laboratories using CTX.  
Strain S-7.1 and S-7.6 exhibited unusual 
phenotypes and genotypes and will be further 
discussed below.  
Overall, in 49 cases the expected confirmation 
of the ESBL- or ampC-producing strain was 
incorrectly detected. Eight of these deviations 
were due to two laboratories not performing the 
confirmatory testing (laboratory #44 and #57). 
Additional 27 deviations were caused by the 
strain S-7.6 with an unusual phenotype, two 
deviating results were caused by S-7.4, a non-
ampC-strain registed as ampC-producer, five 
cases represent participants who have detected 
and confirmed the test strains as expected but 
incorrectly submitted ‘confirmed’ as a result in 
the database. The remaining seven deviations 
were related to handling of the strains or other 
procedures in the laboratory and caused an 
incorrect positive or an incorrect negative 
answer.  
In three cases, resistance to cephalosporins 
was registered for a non-ESBL-producing strain  
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Table 3: Overview of ESBL-producing Salmonella test strains and proportion of laboratories that obtained the expected 
result; number and percentages of laboratories which correctly detected and confirmed the ESBL-producing Salmonella 
strains. Fields shaded in grey with numbers in italics indicate an unexpected result. 
 Strain S-7.1 Strain S-7.2 Strain S-7.3 Strain S-7.6 
ESBL-genes harboured in the test strain 
blaCTX-M-15 
blaOXA-30 
blaTEM-1 
blaCTX-M-15 
blaOXA-10 
blaTEM-1 
blaCTX-M-9 
blaTEM-1 
blaACC-1 
ESBL-producing or ampC-producing strain ESBL ESBL ESBL ampC 
Confirmed ESBL-producer 30/35 (86%) 32/35 (91%) 31/35 (89%) 5/35 (14%) 
ampC confirmed 4/35 (11%) 2/35 (6%) - 11/35 (31%) 
Confirmed MBL - - - 1/35 (3%) 
 
 
Figure 5: Individual participants’ deviations in percent of their total number of Salmonella AST’s. An asterisk indicates 
that the laboratory performed AST using disk diffusion 
 
Figure 6: Individual participants’ deviations in percent of their total number of Campylobacter AST’s. 
(S-7.4), in one of these cases confirmatory tests 
were not performed and the strain was not 
confirmed as an ESBL-producer, in the two 
other cases the laboratories (#15 and #18) 
found S-7.4 resistant to cefoxitin, and 
consequently registered this strain as ampC-
producing  
3.2.2 Campylobacter trial 
For the Campylobacter strains, 97.9% of AST’s 
were correctly tested. Table 1 presents that the 
variation in the obtained correct results ranged 
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from 95.9-99.0% and Table 2 illustrates that the 
percentage of correct AST per antimicrobial 
was above 96.5% for the Campylobacter test 
strains with nalidixic acid and streptomycin 
exhibiting the lowest level. 
3.3 Deviations by laboratory 
Figure 5 and 6 illustrate the percentage of 
deviations for each participating laboratory. The 
laboratories are ranked according to their 
performance determined by the percentage of 
deviating results in tests with antimicrobials 
recommended by EFSA. These results will be 
the focus of the evaluation in the following 
sections. Obtained results including all 
antimicrobials mentioned in the protocol are 
additionally indicated. 
3.3.1 Salmonella trial  
Thirty-one of the laboratories obtained a result 
within the acceptance limit at 5% deviations for 
the Salmonella strains. The maximum 
percentage of deviations was 6.9%. The 
performance of four (11%) laboratories resulted 
in a deviation level above the level of 
performance expected by the EURL-AR (#42, 
#44, #56, and #57), however, none of the 
laboratories are regarded as outliers. As 
illustrated in Figure 5, deviation levels including 
all antimicrobials mentioned in the protocol 
generally do not vary much from the deviation 
levels regarding EFSA-antimicrobials, only.  
3.3.2 Campylobacter trial 
In the Campylobacter trial most laboratories 
performed very well. Applying the 5% 
acceptance threshold, 23 of 29 participating 
laboratories performed acceptably, with 21 
laboratories having no deviations (Figure 6). Six 
laboratories present a deviation level above the 
5% acceptance level (#29, #32, #36, #39, #40 
and #44) and of these, the three with deviation 
levels at 10.3%, 12.8%, and 15.4% were 
regarded as outliers (#36, #40, and #44).  
Deviation levels including results obtained for 
all antimicrobials mentioned in the protocol 
generally do not vary much from the deviation 
levels including results obtained for 
antimicrobials recommended by EFSA, only.  
Table 4 Obtained values for AST of E. coli ATCC 25922 
by MIC determination. AMP; ampicillin, CTX; 
cefotaxime, FOX; cefoxitin, CAZ; ceftazidime, XNL; 
ceftiofur, CHL; chloramphenicol, CIP; ciprofloxacin, 
GEN; gentamicin, IMI; imipenem, NAL; nalidixic acid, 
SMX; sulphonamides, TET; tetracycline, TMP; 
trimethoprim. 
MIC determination E. coli ATCC 25922 
Anti-
microbial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below 
lower QC 
limit 
Above 
upper QC 
limit 
AMP 0/29 (0%) - - 
CTX 0/29 (0%) - - 
FOX 0/6 (0%) - - 
CAZ 0/25 (0%) - - 
XNL 0/5 (0%) - - 
CHL 0/29 (0%) - - 
CIP 4/29 (14%) - 1 step 
GEN 1/29 (3%) - 1 step 
IMI 0/5 (0%) - - 
NAL 0/29 (0%) - - 
SMX 1/21 (5%) 2 steps - 
TET 0/29 (0%) - - 
TMP 1/28 (4%) - 4 steps 
Table 5 Obtained values for AST of C. jejuni ATCC 
33560 by MIC determination. CHL; chloramphenicol, 
CIP; ciprofloxacin, ERY; erythromycin, GEN; 
gentamicin, NAL; nalidixic acid, TET; tetracycline. 
MIC determination C. jejuni ATCC 33560 
Anti-
microbial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below 
lower QC 
limit 
Above 
upper QC 
limit 
CHL 0/20 (0%) - - 
CIP 1/28 (4%) - 4 steps 
ERY 1/28 (4%) 1 step - 
GEN 1/27 (4%) 1 step - 
NAL 0/26 (0%) - - 
TET 0/26 (0%) - - 
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3.4 Deviations by reference strains  
In the following section, deviations are defined 
as results of antimicrobial susceptibility tests on 
the reference strain that are outside the quality 
control (QC) acceptance intervals (App. 7). 
Values from the participants’ testing of the QC 
strains are listed in Appendix 6a and 6b, and in 
Table 4. For the Salmonella trial, all laboratories 
but one (#44) performed QC testing of the 
reference strain. For the Campylobacter trial, all 
29 participating laboratories uploaded data from 
QC-testing on the reference strain. 
Appendix 6a indicates that of laboratories 
performing disk diffusion to test the E. coli 
reference strain (ATCC 25922), all but one (#57 
for ceftiofur) of the obtained results were within 
the QC-range. 
The use of MIC determination for AST of the 
reference strain E. coli ATCC 25922 resulted in 
submission of data from 29 laboratories, six of 
which produced one value each outside the 
QC-limit as illustrated in Table 4.  
All 29 participating laboratories performed MIC 
determination for the C. jejuni reference strain 
ATCC 33560. Table 5 presents the proportion of 
the laboratories with results for the QC strain 
below or above the QC interval. Three 
deviations were seen, divided between two 
laboratories (#21 and #29). 
3.5 Genotypic characterisation 
For the optional genotypic characterisation of 
the ESBL-producing Salmonella test strains, 11 
laboratories participated. In Appendix 10, 
information is collected on detected genes, 
genes which were tested but not detected, 
primers used, and references for the method 
used. One laboratory performed whole genome 
sequencing of the ESBL-producing Salmonella, 
two laboratories performed microarray, and 
eight laboratories performed various types of 
conventional PCR to identify the relevant 
genes. 
Table 6 indicates that the results on gene level 
are very good, whereas for the variants some 
laboratories have submitted results not 
corresponding to the expected. Also, for each of 
the four ESBL-producing test strains, additional 
genes/variants not correlating with the expected 
have been suggested. One of the additional 
genes (S-7.6; TEM) was suggested by a 
laboratory performing microarray whereas the 
remaining addition genes/variants were 
identified by laboratories performing 
conventional PCR. 
Table 6: Results from the participation of eleven laboratories in the optional genotypic characterisation component of the 
EQAS 
Test strain Expected gene Proportion of correct results (gene level) 
Proportion of correct 
results (variant level) 
Additional genes/variants 
identified 
S-7.1 
CTXM-15 9/9 (100%) 6/7 (86%) CTXM-1 
OXA-31 
SHV 
OXA-30 6/6 (100%) 2/3 (67%) 
TEM-1 7/7 (100%) 5/5 (100%) 
S-7.2 
CTXM-15 9/9 (100%) 6/7 (86%) CTXM-1 
OXA-30 
OXA-31 
OXA-10 6/6 (100%) 1/3 (33%) 
TEM-1 7/7 (100%) 5/5 (100%) 
S-7.3 
CTXM-9 9/9 (100%) 6/7 (86%) 
CTXM-4 
TEM-1 6/6 (100%) 4/4 (100%) 
S-7.6 ACC-1 9/9 (100%) 4/4 (100%) TEM 
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4. Discussion 
4.1 Salmonella trial  
Overall, the percentage of correct antimicrobial 
susceptibility test results of Salmonella was 
99.0%. The majority (n=31) of participants 
obtained satisfactory results according to the 
level of acceptance (<5% deviation). A 
significant difference (p<0.01) was obtained 
when comparing results obtained by the use of 
disk diffusion and a MIC method. 
As indicated in Figure 3, the overall quality of 
the results in the 2012-EQAS would appear to 
be at the same level or increasing compared to 
the performance in the former iterations.  
Salmonella test strain S-7.3 had the lowest 
level of compliance between submitted and 
expected results (97.4%) and the analysis of 
possible causes for deviations indicate that they 
are mainly caused by a mix-up of strains in 
laboratory #42.  
The testing of ciprofloxacin towards strains 
exhibiting reduced susceptibility to this 
antimicrobial and the correct interpretation of 
these results when performing disk diffusion 
caused problems for one laboratory (#57). This 
laboratory has subsequently been encouraged 
to apply the recommendations published by 
Cavaco and Aarestrup (2009). These guidelines 
describe the use of 1µg or 5µg ciprofloxacin 
disks together with a lower cut off value for 
detection of plasmid-mediated resistance 
phenotypes when performing DD for AST and 
would detect the resistance phenotype in the 
Salmonella test strain S-7.8 (qnrS1) which had 
an increased ciprofloxacin-MIC but did not 
exhibit nalidixic acid resistance. The guidelines 
appear to have been applied by the other four 
participants of the EURL-AR Salmonella EQAS 
performing DD for AST.  
As indicated by Figure 5, deviation levels higher 
than 5% were exhibited by four laboratories 
(#42, #44, #56, and #57). In two cases (#42 
and #44), these deviation levels appear to be 
caused by a technical error causing mix-up of 
strains in the laboratory, whereas one 
laboratory (#56) appears to have an issue with 
reading the inhibition zone of sulphonamides (a 
bacteriostatic antimicrobial for which the 
inhibition zone must be read at 80% inhibition) 
and one laboratory (#57) performs AST by DD 
which requires the introduction of the guidelines 
recommended in the protocol to detect low-level 
resistance phenotypes. None of these 
laboratories were defined as outliers. 
For the E. coli reference strain, the obtained 
results were in general in agreement with the 
CLSI recommendations. The number of 
laboratories performing AST on Salmonella by 
the use of disk diffusion was five. Four of these 
uploaded data for the testing of the reference 
strain with a total of 100% within range. For the 
laboratories performing AST on Salmonella by 
an MIC-method, two laboratories each 
submitted a result one MIC-step above the QC-
range whereas one laboratory (#4) for 
sulphonamides and trimethoprim submitted a 
value two steps below and four steps above the 
QC-range, respectively. This laboratory should 
perform trouble shooting to follow up on the 
reason for the unexpected result. Laboratory 
#44 did not submit QC-results of the E. coli 
reference strain and is recommended to do so 
for future EURL-AR EQAS. 
Laboratories #4, #26, #38, and #40 which had a 
deviation level above the acceptance limit in 
EQAS 2011 with values of 5.1%, 6.4%, 5.1%, 
and 7.7%, respectively, have increased their 
performance considerably to a deviation level in 
the 2012-iteration at 0%, 0%, 1.5%, and 1.4%, 
respectively. Laboratory #54 (deviation level at 
9.3% in 2011) did not participate in the 2012-
iteration. 
ESBL-producing Salmonella test strains 
ESBL-producing microorganisms are an 
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emerging problem worldwide, and it should be 
of a high priority for the NRLs to be able to 
detect them. It was therefore decided at the 
EURL-AR Workshop in June 2008, that the 
detection of ESBL-producing test strains should 
be included as a mandatory test in this EQAS. 
Four of the Salmonella test strains were ESBL-
producers (S-7.1, S-7.2, S-7.3 and S-7.6), and 
the participants were asked to interpret their 
results according to the description in the 
protocol. Of the 35 laboratories which tested 
Salmonella, two (#44 and #57) did not submit 
results for confirmatory testing of ESBL-
production and therefore they obtained an 
evaluation as incorrect.  
Two of the included ESBL-producing strains 
exhibited an unusual phenotype. One was an 
extremely drug resistant strain (S-7.1) that 
among resistance to many other antimicrobials 
also exhibited phenotypic resistance to cefoxitin 
with an MIC at 16. The strain harboured OXA-
30 together with TEM-1 and CTX-M-15. For this 
particular strain, synergy was seen between 
both CTX:CTX/Cl and CAZ:CAZ/Cl and a high 
MIC for cefoxitin. In this case, the high MIC for 
cefoxitin does not, however, indicate an ampC-
genotype. This is based on the fact that a strain 
with an ampC-genotype together with an ESBL-
genotype, would not show phenotypically as 
synergy between CTX:CTX/Cl or CAZ:CAZ/Cl. 
The other strain with an unusual pheno-
/genotype was strain S-7.6. The strain exhibited 
resistance to cefotaxime and ceftazidime (and 
ceftiofur), but when attempting to confirm the 
ESBL-production by testing for synergy with 
clavulanic acid, ESBL-production could not be 
confirmed, nor did the strain show resistance to 
cefoxitin. Consequently, the results from the 
phenotypic testing could not confirm ampC- or 
ESBL-production. In a genotypic analysis, 
however, the strain was found to harbour 
blaACC-1. The organizers concluded that the fact 
that this strain is phenotypically resistant to 
cephalosporins should induce the participant to 
suspect that the strain harboured one type or 
another of ESBL- or ampC-producing gene and 
should then demand further investigation, 
including molecular testing. 
If leaving out of account the results from the 
strain with the particularly unusual phenotype 
(S-7.6) and the two laboratories which did not 
perform confirmatory testing, the results 
submitted from the 33 laboratories performing 
confirmatory testing were 94% in accordance 
with the expected. The seven results not in 
concordance with the expected and relevant for 
discussion were caused by various problems 
with confirmatory testing causing an incorrect 
positive or an incorrect negative answer. These 
deviations were submitted by five different 
laboratories and thus do not indicate methodical 
issues at particular laboratories.  
In general, it is recommended that more than 
one cephalosporin is used for the detection of 
an ESBL-producing Salmonella when initially 
screening the isolate. The cephalosporins 
cefotaxime, cefpodoxime, ceftiofur, ceftriaxone, 
and ceftazidime were all found useful in 
detecting isolates with ESBL or plasmidic ampC 
by Aarestrup et al. (2010), however, cefotaxime, 
cefpodoxime, and ceftriaxone were superior to 
ceftiofur and ceftazidime.  
Laboratory #44 and #57 have been contacted 
directly due to the absent confirmatory tests.  
4.2 Campylobacter trial  
The overall percentage of correct antimicrobial 
susceptibility test results of Campylobacter was 
97.9%. The performance varied from no 
deviations to 15.4% deviations, with 23 
laboratories performing satisfactorily according 
to the established acceptance ranges. Six 
laboratories (#29, #32, #36, #39, #40, and #44) 
obtained deviation levels above 5%, three of 
these were defined as outliers (#36, #40, and 
#44) with deviation levels at 10.3%, 12.8%, and 
15.4%. For one laboratory (#29), the values 
obtained for the QC-strain indicate that trouble 
shooting might be necessary to identify if any 
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methodical issues is the reason for the obtained 
deviations. For two laboratories (#36 and #44) it 
appears that the interpretation of the obtained 
MIC-values has been done with reference to 
other interpretative criteria than those in the 
protocol. For the remaining number of 
laboratories, no obvious type of mistake 
appears, however it is notable that for each of 
laboratories #32, #39, and #40, three, three and 
four of the deviations are on AST’s of one of the 
tested strains; C-7.5, C-7.8 and C-7.4, 
respectively, indicating an issue with that 
particular strain. 
All participating laboratories uploaded data from 
tests performed on the C. jejuni reference strain 
and the proportion of results within the QC 
intervals was 98.1%. The three values outside 
the QC intervals were obtained by two 
laboratories (#21 and 29) of which one had no 
deviation in the test strains and one had a 
deviation level at 7.7% (laboratory #29).  
Laboratories #4, #19, and #39 which were 
regarded as outliers with deviation levels in 
EQAS 2011 at 25%, 17.5%, and 10% in 2011, 
respectively, all increased their performance in 
the 2012-iteration and obtained deviation levels 
at 0%, 0% and 5.1%, respectively. 
4.3 Genotypic characterisation 
The focus on genotypic characterization of 
microorganisms is increasing in the EU and 
worldwide. In EU, method proposals are 
underway for the detection and confirmation of 
ESBL-producing Enterobacteriaceae and in this 
context the inclusion of sequencing methods for 
the genotypic characterisation of relevant genes 
are currently being considered. The optional 
genotypic characterisation offered as a 
supplementary part of this EQAS should 
therefore be seen as an important possibility for 
the NRL-AR’s to introduce this method in the 
laboratory and thereby be at the forefront when 
the method proposals are adopted. This year, 
11 laboratories participated in this optional 
EQAS item and all obtained satisfying results.  
 
5. Conclusions 
The goal of the EURL-AR EQAS is to have all 
participating NRLs performing antimicrobial 
susceptibility testing of Salmonella and 
Campylobacter with a deviation level below 5%. 
This seems within reach for Salmonella as well 
as for Campylobacter.  
The performance of the NRL’s appear to be at 
the same level for Salmonella AST’s in this 
EQAS (99.0%) when compared to the results 
from the EQAS 2009, 2010 and 2011 (98.4%, 
97.8% and 98.1). Regarding Campylobacter 
AST’s, the level of deviation also appears to be 
quite stable with a level at 2.1% in 2012 
compared to 2.2%, 2.0% and 1.9% in 2009, 
2010 and 2011. Three laboratories were 
regarded as outliers for the Campylobacter AST 
(#36, #40, and #44) with deviation levels at 
10.3%, 12.8%, and 15.4% 
The current EQAS iteration included both the 
phenotypic and the genotypic testing of ESBL-
producing Enterobacteriaceae. These bacteria 
are of great concern in the EU and worldwide 
due to their emergence in various reservoirs 
and the detection of these resistances should 
therefore be prioritized by the national 
reference laboratories performing AST of 
Enterobacteriaceae.  
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EQAS 2012  
FOR SALMONELLA, CAMPYLOBACTER AND OPTIONAL GENOTYPIC CHARACTERISATION 
The EURL-AR announces the launch of another EQAS, thus providing the opportunity for 
proficiency testing which is considered an essential tool for the generation of reliable laboratory 
results of consistently good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight Salmonella isolates and eight 
Campylobacter isolates. For the optional genotypic characterisation, the ESBL-genes in the relevant 
strains should be detected. Additionally, quality control (QC) strains E. coli ATCC 25922 (CCM 
3954) and C. jejuni ATCC 33560 (CCM 6214) will be distributed to new participants.  
This EQAS is specifically for NRL’s on antimicrobial resistance. Therefore, laboratories designated 
to be NRL-AR do not need to sign up to participate but are automatically regarded as participants. 
Participation is free of charge for all designated NRL-AR’s.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B”: Eight Salmonella strains, 
eight Campylobacter and for new participants also the QC strains mentioned above. Please provide 
the EQAS coordinator with documents or other information that can simplify customs procedures 
(e.g. specific text that should be written on the proforma invoice). To avoid delays, we kindly ask 
you to send this information already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in October 2012. The protocol for 
this proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than 
December 14th 2012 via the password-protected website.  
Upon reaching the deadline, each participating laboratory is kindly asked to enter the password-
protected website once again to download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In 
the report, laboratories will be presented coded, which ensures full anonymity. The EURL-AR and 
the EU Commission, only, will have access to un-coded results. The report will be publicly 
available. 
 
Next EQAS: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing 
of E. coli, staphylococci and enterococci which will be carried out in June 2013.  
Please contact me if you have comments or questions regarding the EQAS. 
Sincerely, 
 
 
Susanne Karlsmose (suska@food.dtu.dk) 
EQAS-Coordinator 
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Participant list
Salmonella Campylobacter Genotypic characterisation Institute  Country
X X - Austrian Agency for Health and Food Safety Austria
X X X Institute of Public Health Belgium
X X - Nacional Diagnostic and Research Veterinary Institute Bulgaria
X - - Croatian Veterinary Institut Croatia
X X - Veterinary Services Cyprus
X X X State Veterinary Institute Praha Czech Republic
X X X National Food Institute Denmark
X X - Estonian Veterinary and Food Laboratory Estonia
X X - Finnish Food Safety Authority EVIRA Finland
X - - ANSES Maisons Alfort France
- X - ANSES Ploufragan France
X X - ANSES Lyon France
X - - ANSES Fougères France
X X X Federal Institute for Risk Assessment Germany
X - - Veterinary Laboratory of Chalkis Greece
X X - Central Agricultural Office Veterinary Diagnostic Directorate Hungary
X X - Central Veterinary Research Laboratory Ireland
X X X Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
X X - Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia
X X - National Food and Veterinary Risk Assessment Institute Lithuania
X X - Public Health Laboratory Malta
X X - Food and Consumer Product Safety Authority (VWA) Netherlands
X X X Central Veterinary Institute of Wageningen UR Netherlands
X X - Veterinærinstituttet Norway
X X - National Veterinary Research Institute Poland
X X - Laboratorio National de Investigacáo Veterinaria Portugal
X X - Institute for Hygiene and Veterinary Public Health Romania
X X X Institute for Diagnosis and Animal Health Romania
- - - Institute of Veterinary Medicine of Serbia Serbia
X X - State Veterinary and Food Institute  (SVFI) Slovakia 
X X - National Veterinary Institute Slovenia
- - - Laboratorio Central de Sanidad, Animal de Santa Fe (only Staph) Spain
X X X Laboratorio Central de Sanidad, Animal de Algete Spain
X X - VISAVET Health Surveillance Center, Complutense University Spain
X - - Centro nacional de Alimentacion. Agencia Espanola de Seguridad Alimentria y Nutricion Spain
X X X National Veterinary Institute, SVA Sweden
X X X Vetsuisse faculty Bern, Institute of veterinary bacteriology Switzerland
X - - National Food Reference Laboratory Turkey
X X - Centre for Infections Health Protection Agency United Kingdom
X X X The Veterinary Laboratory Agency United Kingdom
Designated NRL-AR by the compentent authority of the member state
Non-NRL-AR enroled by the EURL
Not a Member State of the EU
Appendix 3a, page 1 of 1
Salmonella  test strains and reference values (MIC-value and interpretation)
Ampicillin Cefotaxime ESBL Ceftazidime ESBL Cefoxitin Ceftiofur Chloramphenicol Ciprofloxacin Gentamicin Imipenem Nalidixic acid Sulfamethoxazole Tetracycline Trimethoprim
AMP CTX CTX:CTX/Cl CAZ CAZ:CAZ/Cl XNL CHL CIP GEN IMI NAL SMX TET TMP
EURL S-7.1  > 32 RESIST > 64 RESIST ratio >= 8  = 64 RESIST ratio >= 8 16 RESIST  > 8 RESIST  > 64 RESIST  > 4 RESIST  > 16 RESIST <= 0.5 SUSC  > 64 RESIST  > 1024 RESIST  > 32 RESIST  > 32 RESIST
EURL S-7.2  > 32 RESIST > 64 RESIST ratio >= 8  = 128 RESIST ratio >= 8 8 SUSC  > 8 RESIST  > 64 RESIST  > 4 RESIST  > 16 RESIST <= 0.5 SUSC  > 64 RESIST  > 1024 RESIST  > 32 RESIST  > 32 RESIST
EURL S-7.3  > 32 RESIST = 16 RESIST ratio >= 8 (E-test: phantom)  = 1 SUSC ratio < 8 4 SUSC  > 8 RESIST  = 4 SUSC  = 0.5 RESIST <= 0.5 SUSC <= 0.5 SUSC  > 64 RESIST  = 32 SUSC  > 32 RESIST <= 1 SUSC
EURL S-7.4  > 32 RESIST  = 0.25 SUSC  = 0.5 SUSC  = 1 SUSC  = 16 SUSC  = 0.5 RESIST  <= 0.5 SUSC  > 64 RESIST  > 1024 RESIST  = 4 SUSC  > 32 RESIST
EURL S-7.5 <= 1 SUSC <= 0.12 SUSC  = 0.25 SUSC  <= 0.5 SUSC  =  8 SUSC  = 0.03 SUSC  = 1 SUSC  = 4 SUSC  = 64 SUSC <= 2 SUSC <= 1 SUSC
EURL S-7.6  = 32 RESIST = 16 RESIST ratio < 8  = 32 RESIST ratio < 8 4 SUSC  > 8 RESIST  = 8 SUSC  <= 0.015 SUSC  = 1 SUSC <= 0.5 SUSC  = 4 SUSC  = 64 SUSC <= 2 SUSC <= 1 SUSC
EURL S-7.7  = 2 SUSC  = 0.25 SUSC  = 0.25 SUSC   = 1 SUSC  = 4 SUSC  = 0.25 RESIST  = 0.5 SUSC  > 64 RESIST  > 1024 RESIST  > 32 RESIST  > 32 RESIST
EURL S-7.8 <= 1 SUSC <= 0.12 SUSC  = 0.5 SUSC  <= 0.5 SUSC  > 64 RESIST  = 0.5 RESIST  = 0.5 SUSC  = 4 SUSC  = 32 SUSC <= 2 SUSC <= 1 SUSC
Resistant
Appendix 3b, page 1 of 1
Campylobacter  test strains and reference values (MIC-value and interpretation)
Chloramphenicol Ciprofloxacin Erythromycin Gentamicin Nalidixic acid Streptomycin Tetracycline
Species Code CHL CIP ERY GEN NAL STR TET
C. coli EURL C-7.1  = 4 SUSC  = 0.25 SUSC  >  64 RESIST  = 0.5 SUSC  = 8 SUSC  = 2 SUSC  = 2 SUSC
C. coli EURL C-7.2  = 4 SUSC  = 0.25 SUSC  > 64 RESIST  =1 SUSC  = 8 SUSC  = 4 SUSC  = 64 RESIST
C. coli EURL C-7.3  = 8 SUSC  = 0.06 SUSC  = 1 SUSC  = 0.5 SUSC  = 4 SUSC  <= 1 SUSC  = 0.5 SUSC
C. coli EURL C-7.4  = 8 SUSC  = 32 RESIST  = 8 SUSC  = 0.5 SUSC  > 64 RESIST  > 16 RESIST  > 64 RESIST
C. jejuni EURL C-7.5  = 4 SUSC  = 8 RESIST  = 1 SUSC  = 0.5 SUSC  > 64 RESIST  > 16 RESIST  = 0.12 SUSC
C. jejuni EURL C-7.6  = 4 SUSC  = 16 RESIST  > 64 RESIST  > 32 RESIST  > 64 RESIST  > 16 RESIST  = 64 RESIST
C. jejuni EURL C-7.7   <= 2 SUSC  = 0.12 SUSC  = 1 SUSC  = 0.25 SUSC  = 4 SUSC  <= 1 SUSC = 32 RESIST
C. jejuni EURL C-7.8  = 4 SUSC  > 4 RESIST  = 2 SUSC  = 0.25 SUSC  > 64 RESIST  <= 1 SUSC  = 32 RESIST
Resistant
 
 
M00-06-001/01.12.2011  
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Welcomeletter: 
EURL-AR External Quality Assurance System 2012 
- Salmonella, Campylobacter and optional genotypic characterisation 
 
Id: «Lab_no_» 
«Name» 
«Institute__» 
«Country» 
Kgs. Lyngby, October 2012 
Dear «Name», 
 
Please find enclosed the bacterial strains for the EURL-AR EQAS 2012. Upon arrival to your 
laboratory, the strains should be stored dark and at 4°C for stabs, and dark and cool for freeze-
dried strains. Charcoal swabs must be subcultured straight away.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for the EURL-AR 
EQAS are available: 
- Protocol for Salmonella and Campylobacter including test forms 
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Control Strains 
 
We ask you to examine the eight Salmonella and the eight Campylobacter strains that we send to 
you by performing antimicrobial susceptibility testing. The ESBL-producing Salmonella strains 
should be characterised genotypically (optional) according to the description in the protocol. In the 
protocol you can find detailed description of the procedures to follow. Additionally, you can find a 
description of the procedure to enter your results into the interactive web database. For accessing 
the database, you need this username and password. 
 
 
Your username: «Username» 
 
Your password: «Password» 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
 
Results should be returned to us no later than December 14th
 
 2012. 
Please acknowledge receipt of this parcel immediately upon arrival (to suska@food.dtu.dk).  
Do not hesitate to contact us for further information. 
 
Yours sincerely, 
 
Susanne Karlsmose 
EQAS-Coordinator 
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2012 
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PROTOCOL  
For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional 
genotypic characterisation of ESBL-producing strains 
 
 
1 INTRODUCTION    ................................................................................................................. 1
2 OBJECTIVES    ....................................................................................................................... 2
3 OUTLINE OF THE EQAS 2012    ......................................................................................... 2
3.1 Shipping, receipt and storage of strains    ..................................................................... 2
3.2 Suggested procedure for reconstitution of the lyophilised reference strains    ......... 2
3.3 Susceptibility testing    .................................................................................................... 2
3.4 Optional genotypic characterisation    .......................................................................... 5
4 REPORTING OF RESULTS AND EVALUATION    ......................................................... 6
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE   ........................... 7
 
 
1 INTRODUCTION 
One of the tasks as the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR) is to 
organise and conduct an External Quality Assurance System (EQAS) on antimicrobial susceptibility 
testing (AST) of Salmonella and Campylobacter. The Salmonella and Campylobacter EQAS 2012 
includes susceptibility testing of eight Salmonella and eight Campylobacter strains together with 
susceptibility testing of the reference strains E. coli ATCC 25922 (CCM 3954) and C. jejuni ATCC 
33560 (CCM 6214). Additionally, optional characterisation of the genes conferring ESBL-
production in the Salmonella test strains is offered. 
For new participants of the EQAS who have not already received the mentioned reference strains, 
these are included in the parcel. The reference strains will not be included in the years to come. The 
reference strains are original certified cultures and are free of charge. Please take proper care of the 
strains. Handle and maintain them as suggested in the manual ‘Subculture and Maintenance of QC 
Strains’. Please use them for future internal quality control for susceptibility testing in your 
laboratory.  
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For this EQAS, members of the Food- and Waterborne Diseases and Zoonoses Programme (FWD) 
based at ECDC are also participating, however, for these participants the EQAS has been slightly 
adjusted. Description of this can be found in this protocol, i.e. that for antimicrobial susceptibility 
testing (AST) of Campylobacter, results obtained by in-house methods like disk diffusion or E-test 
are also accepted. 
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
2 OBJECTIVES 
The main objective of this EQAS is to support laboratories to assess and if necessary improve the 
quality of susceptibility testing of pathogens originating from food and animal sources, especially 
Salmonella and Campylobacter. Furthermore, to assess and improve the comparability of 
surveillance and antimicrobial susceptibility data reported to EFSA by different laboratories on 
Salmonella and Campylobacter and to harmonise the breakpoints used within the EU. 
3 OUTLINE OF THE EQAS 2012 
3.1 Shipping, receipt and storage of strains 
In October 2012, the EU appointed National Reference Laboratories will receive a parcel from the 
National Food Institute containing eight Salmonella and eight Campylobacter strains. QC reference 
strains will be included for participants who have not previously received these. Some of the 
Salmonella test strain are ESBL-producing, and are included as test strains in the optional part of the 
EQAS consisting of characterisation of genes conferring ESBL-production.  
The reference strains are shipped lyophilised, the Campylobacter test strains are shipped as a 
charcoal swabs and the Salmonella test strains are stab cultures. On arrival, the stab cultures and the 
charcoal swabs must be subcultured, and all cultures should be kept refrigerated until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below.  
3.2 Suggested procedure for reconstitution of the lyophilised reference strains  
Please see the document ‘Instructions for opening and reviving lyophilised cultures’ on the EURL-
AR-website (see www.eurl-ar.eu). 
3.3 Susceptibility testing 
The strains should be susceptibility tested towards as many as possible of the following 
antimicrobials by the method used in the laboratory when performing monitoring for EFSA. For 
Appendix 4b, page 2 of 8
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2012 
 
 
Page 3 of 8 
DFVF- M00-06-001/24.10.2011 
MIC the cut off values listed in Tables 1 and 2 should be used. The epidemiological cut-off values 
allow two categories of characterisation – resistant or sensitive.  
Participants using disk diffusion are recommended to interpret the results according to their 
individual breakpoints, categorising them into the terms resistant and susceptible. A categorization 
as intermediary is not accepted; therefore intermediary results should be interpreted as 
susceptible. Interpretations in concordance with the expected value will be categorised as ‘correct’, 
whereas interpretations that deviate from the expected interpretation will be categorised as 
‘incorrect’.  
The cut off values used in the interpretation of the MIC results are developed by EUCAST 
(www.eucast.org). 
With regard to MIC range and/or disc content we ask you to fill in these pieces of information in the 
database. Also, if you do not use
 
 the cut-off values listed in the protocol for interpretation of the 
susceptibility results, please fill in or update the breakpoints used, in the database. 
3.3.1 Salmonella. 
Testing of gentamicin
Antimicrobials for Salmonella 
 may be of value for monitoring. Please, do not take into account in this study, 
that the CLSI guidelines state that for aminoglycosides Salmonella should not be reported as 
susceptible. 
MIC (µg/mL) 
R is > 
Ampicillin (AMP) 8 
Cefotaxime (CTX) 0.5 
Ceftazidime (CAZ)** 2 
Ceftiofur (XNL)** 2 
Chloramphenicol (CHL) 16 
Ciprofloxacin (CIP) 0.06 
Gentamicin (GEN) 2 
Nalidixic acid (NAL) 16 
Sulphonamides (SMX)* 256 
Tetracycline (TET) 8 
Trimethoprim (TMP) 2 
Table 1: Interpretative guidelines for Salmonella  
* CLSI     
** Not part of the EFSA monitoring programme (used for confirmatory tests for ESBL production) 
 
Also, when following EUCAST epidemiological cut-off values, Salmonella resistant to nalidixic 
acid should also be interpreted as resistant to ciprofloxacin. When using disc diffusion and CLSI 
clinical breakpoints this connection between nalidixic acid and ciprofloxacin is not taken into 
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account. Thus, the result in this situation with regard to ciprofloxacin will deviate from the expected 
result in this EQAS. 
Important notes: beta-lactam resistance
Confirmatory tests for ESBL production is mandatory on all strains resistant to cefotaxime (CTX), 
ceftazidime (CAZ) and/or ceftiofur (XNL). 
: 
Confirmatory test for ESBL production requires use of both cefotaxime (CTX) and ceftazidime 
(CAZ) alone and in combination with a β-lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. its MIC when tested alone (E-test 3 dilution steps difference; 
MIC CTX : CTX/CL or CAZ : CAZ/CL ratio ≥ 8) or ii) a ≥ 5 mm increase in a zone diameter for 
either antimicrobial agent tested in combination with clavulanic acid vs. its zone when tested alone 
(CLSI M100 Table 2A; Enterobacteriaceae). The presence of synergy indicates ESBL production. 
Confirmatory test for Metallo-beta-lactamase (MBL) production requires use of imipenem (IMI) 
and IMI/EDTA. Synergy is defined as a ≥ 3 twofold concentration decrease in the MIC for the 
combination IMI/EDTA vs. MIC for IMI alone (E-test 3 dilution steps difference, MIC IMI : 
IMI/EDTA ratio ≥ 8; CLSI M100, Table 2A; Enterobacteriaceae). The presence of synergy indicates 
MBL production. 
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase, that should be verified by PCR and sequencing. 
The EURL-AR aims to harmonise with EUCAST expert rules. Accordingly, MIC values and 
relative interpretation of cefotaxime, ceftazidime and/or ceftiofur used for detection of beta-
lactamase-producing strains in this EQAS should be reported as found.  
 
3.3.2 Campylobacter   
Please find information on the test forms showing which test strains are C. jejuni and C. coli, 
respectively. 
For AST of Campylobacter only MIC methods are recommendable, i.e. broth or agar dilution 
methods. The EURL-AR does not recommend the use of either disk diffusion or E-test for AST of 
Campylobacter. Laboratories in the EURL-AR network should test the sub-cultured Campylobacter 
by the use of microbroth or agar dilution using incubation at 36-37ºC for 48 hours or 42ºC for 24 
hours.  
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Antimicrobials for Campylobacter MIC (µg/mL) R is > 
MIC (µg/mL) 
R is > 
 C. jejuni C. coli 
Chloramphenicol* 16 16 
Ciprofloxacin 0.5 0.5 
Erythromycin 4 8 
Gentamicin 2 2 
Nalicixic acid* 16 16 
Streptomycin 4 4 
Tetracycline 1 2 
Table 2: Interpretative guidelines for Campylobacter  
*Not part of the EFSA monitoring programme 
  
 
For the laboratories of the FWD-network, results of AST of Campylobacter may be obtained by in-
house methods like disk diffusion or E-test. In this case, in-house interpretative criteria must be 
applied. 
 
3.4 Optional genotypic characterisation 
For the optional genotypic characterisation of the ESBL-producing Salmonella test strains, the 
requested results are the genes conferring ESBL-production harboured in the test strains. The genes 
included in the test are the following: ACC, ACT, CMY, CTX, DHA, FOX, GES, IMP, KPC, 
MOX, NDM, OXA, PER, SHV, TEM, VEB, and VIM. The database lists the relevant variants of 
the genes.  
When uploading the results in the database, the identified genes will be evaluated against the 
expected results. The results will be evaluated on the detected gene (ACC-, ACT-, CMY-, etc.) as 
well as the variant identified.  
The method used for the genotypic characterisation should be your laboratory’s routine method. The 
expected results listed in the database are those obtained by the EURL-AR.  
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4 REPORTING OF RESULTS AND EVALUATION 
Test forms are available for recording your results before you enter them into the interactive web 
database. We kindly ask you to report in the database the tested MIC range and/or antimicrobial disk 
content. If you did not 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database.  Results must be submitted no later than 14th December 2012. 
use the cut-off values recommended in the protocol for interpretation of 
AST results, please report the breakpoints used. 
After 
the deadline, the database will be closed and you will be able to view and print an automatically 
generated report evaluating your results.
If you do not have access to the Internet, or if you experience difficulties in entering your results, try 
a few days later or, alternatively, return the completed test forms by e-mail, fax or mail to the 
National Food Institute, Denmark.  
 Results in agreement with the expected interpretation are 
categorised as ‘correct’, while results deviating from the expected interpretation are categorised as 
‘incorrect’. 
All results will be summarised in reports available to all participants. The data will be collected in 
an overall summary report in which anonymous laboratory results will be analyzed. This summary 
report will focus on comparing the results from the EURL-AR network, and public health 
laboratories (FWD-laboratories) to assess the level of harmonization need.    
In addition, separate reports for the EURL-AR network (by DTU) and for public health laboratories 
(by ECDC) will be prepared.  
The data in the report will be presented with laboratory codes. A laboratory code is only known to 
the individual laboratory, while the complete list of laboratories and their respective codes is 
confidential and only known to the EURL-AR (all participants), the ECDC (FWD-laboratories) and 
the EU Commission (NRL-ARs). All conclusions and all three reports will be publicly available.  
If you have any questions, please do not hesitate to contact the EQAS Coordinator: 
 
Susanne Karlsmose 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6601 
Fax: +45 3588 6341 
E-mail: suska@food.dtu.dk 
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5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read this passage before entering the web page. Before you go ahead, you need your test form 
by your side together with your breakpoint values.  
You are able to browse back and forth by using the forward and back keys or click on the EURL 
logo. 
You enter the EURL-AR EQAS web page (http://thor.dfvf.dk/crl) then write your username and 
password in low cases and press enter. Your username and password is the same as in the previous 
EQAS’s arranged by the National Food Institute. If you have problems with the login please contact 
us. 
Click on either “Salmonella test results” or “Campylobacter test results” depending on your results. 
The below description is aimed at Salmonella entry but is exactly the same as for Campylobacter 
entry. 
Click on "Start of Data Entry - Methods and Breakpoints for Salm.” 
In the next page you navigate to fields with the Tab-key and mouse.  
Fill in what kind of method you have used for the susceptibility testing of Salmonella and the brand 
of discs, tablets, MIC trays etc.  
Fill in the relevant information, either disk content or MIC range. If you use disk diffusion, please 
upload the breakpoints used. 
You will find one more box to fill in on this page when testing Campylobacter: Fill in the actual 
incubation condition used for susceptibility testing of Campylobacter – 36°C/48h or 42°C/24h. 
Click on "save and go to next page”  
In the data entry pages for each Salmonella and Campylobacter strain, you enter the obtained value 
and the interpretation as R or S. 
For Salmonella, you also type in results for the ESBL tests. 
If you have not used an antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains please enter the zonediameters in mm or MIC values 
in µg/ml. Remember to use the operator keys to show e.g. equal to, etc. If you do not use CLSI 
guidelines for AST on the reference strains, please add a comment on the method used. 
Click on "save and go to next page" 
This page is a menu, from where you can review the input pages, approve your input and finally see 
and print the evaluated results: 
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Browse through the pages and make corrections if necessary. Remember to save a page if you make 
any corrections. If you save a page without changes, you will see an error screen, and you just have 
to click on "back" to get back to the page and "go to next page" to continue. 
Please fill in the evaluation form. 
Approve your input. Be sure that you have filled in all the results before approval, as  YOU CAN 
ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive database, but 
allows you to see the evaluated results.   
If you have performed the optional genotypic characterisation: 
Click on “Gene test” and follow the description in the database for upload of the results of the 
optional genotypic characterisation. Approve your input. Be sure that you have filled in all the 
results before approval. The approval blocks your data entry in the interactive database, but allows 
you to see the evaluated results. 
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Salmonella and Campylobacter, genetic characterisation 
 
TEST FORMS 
   
 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
EU Community Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2011 
 
 
Appendix 4c, page 2 of 9 
Page 2 of 9 
DFVF- M00-06-001/24.10.2011 
 
TEST FORM                                                            
 
Does your laboratory have an accreditation for Salmonella AST?   Yes     No 
 
Does your laboratory have an accreditation for other laboratory methods/tests?   Yes    No 
 
Which method did you use for antimicrobial susceptibility testing of Salmonella in this EQAS: 
  Broth Microdilution    
  Agar dilution 
  E-test (strips)                                       
  Disk diffusion (paper disks)  
  Rosco Neo Sensitabs (tablets)            
 
Brand of microdilution plate, strips or disks:       
 
Method used for detection of ESBL-producing strains, see pictures of the methods on 
http://www.eurl-ar.eu/201-resources.htm  
 
  E-test 
  Double disk 
  Combination disk                                       
  MIC determination (microbroth)  
  Selective media please specify:       
  Other, please specify        
 
Comments or additional information:       
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TEST FORM          
 
Breakpoints used (zonediameters) and general info regarding disk content and test-range 
used for MIC: 
 
- Please fill in the disk content or the test-range used for MIC, respectively. 
- Please, only fill in breakpoints if you did not use a MIC method, that is, only if you used other 
breakpoints/cut-off values than the ones listed in the protocol for interpretation of AST results for 
Salmonella. Otherwise leave breakpoint fields empty. 
                                                   
 
 
 
 
Antimicrobial  General info 
 
The relevant information in the 
two columns below should be 
filled in 
 
Zonediameter (mm) 
 
Please, only fill in breakpoint information if 
you did not use the cut-off values listed in 
the protocol  
 
Disk content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Sensitive 
(mm) 
 
Ampicillin, AMP             ≤             ≥       
Cefotaxime, CTX             ≤             ≥       
Ceftazidime, CAZ             ≤             ≥       
Ceftiofur, XNL             ≤             ≥       
Chloramphenicol, CHL             ≤             ≥       
Ciprofloxacin, CIP             ≤             ≥       
Gentamicin, GEN             ≤             ≥       
Nalidixic acid, NAL             ≤             ≥       
Streptomycin, STR             ≤             ≥       
Sulphamethoxazole, SMX             ≤             ≥       
Tetracycline, TET             ≤             ≥       
Trimethoprim, TMP               ≤             ≥       
EU Community Reference Laboratory for Antimicrobial Resistance  
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TEST FORM                                                            
 
Does your laboratory have an accreditation for Campylobacter AST?  Yes     No 
 
Does your laboratory have an accreditation for other laboratory methods/tests?  Yes     No 
 
Incubation conditions:     36-37ºC / 48h   42ºC / 24h 
 
Method used for antimicrobial susceptibility testing of Campylobacter in this EQAS:: 
 Microbroth 
 Agardilution 
 In-house (disk diffusion) 
 In-house (E-test) 
 
Brand of broth/agar:       
Additional comments:       
 
How many Campylobacter isolates does your laboratory annually isolate:       
How many Campylobacter isolates does your laboratory annually susceptibility test:       
 
If using an in-house method (disk diffusion or E-test), 
- Please fill in the disk content or the test-range used for E-test, respectively. 
- Please fill in interpretative criteria if you used other breakpoints/cut-off values than the ones listed 
in the protocol for interpretation of AST results for Campylobacter. Otherwise leave breakpoint 
fields empty. 
 
Antimicrobial  General info 
 
The relevant information in the 
two columns below should be 
filled in 
 
Zonediameter (mm) 
 
Please, only fill in breakpoint information if 
you did not use the cut-off values listed in 
the protocol  
 
Disk content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Sensitive 
(mm) 
 
Chloramphenicol             ≤             ≥       
Ciprofloxacin             ≤             ≥       
Erythromycin             ≤             ≥       
Gentamicin             ≤             ≥       
Nalidixic Acid             ≤             ≥       
Streptomycin             ≤             ≥       
Tetracycline             ≤             ≥       
EU Community Reference Laboratory for Antimicrobial Resistance  
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TEST FORM  
Strain  
 
 
Antimicrobial  
Interpretation 
 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Salmonella 
EURL S-6.X 
 
 
Ampicillin, AMP     
  
         
   Cefotaxime, CTX     
  
         
   Ceftazidime, CAZ     
  
         
   Ceftiofur, XNL     
  
         
   Chloramphenicol, CHL     
  
         
   Ciprofloxacin, CIP     
  
         
   Gentamicin, GEN     
  
         
   Nalidixic acid, NAL     
  
         
   Streptomycin, STR     
  
         
   Sulfonamides, SMX     
  
         
   Tetracycline, TET     
  
         
   Trimethoprim, TMP     
  
         
    
All strains resistant against cefotaxime (CTX), ceftazidime (CAZ) or ceftiofur (XNL) should be 
included for confirmatory tests for ESBL production.  
See further description of confirmatory tests above in section ‘3.3.1 Salmonella’. 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX mic ratio    
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
 Incr. in zone diam   
 Incr. ≥ 5 mm (synergy) 
 Incr.< 5 mm 
 
CAZ/CL : CAZ mic ratio  
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
 Incr. in zone diam  
 Incr. ≥ 5 mm (synergy) 
 Incr.< 5 mm 
 
Cefoxitin, FOX mic value   MIC value > 16   MIC value ≤ 16  Zone diameter  
 D ≤ 14 mm  
 D > 14 mm 
Imipenem, IMI mic value   MIC value > 1   MIC value ≤ 1 
 Confirmed ESBL 
 Confirmed AmpC 
 Confirmed Metallo betalactamase IMI/E : IMI mic ratio  
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
Comments:      
EU Community Reference Laboratory for Antimicrobial Resistance  
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TEST FORM                                                            
 
Susceptibility testing of E. coli referencestrain ATCC 25922 
 
Strain 
 
 
 
Antimicrobial  
 
Zonediameter (mm) or  
MIC-value (μg/ml) 
E. coli ATCC 25922 
 
 
 
 
Ampicillin, AMP       
Cefotaxime, CTX       
Cefoxitin, FOX       
Ceftazidime, CAZ       
Ceftiofur, XNL       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Gentamicin, GEN       
Imipenem, IMI       
Nalidixic acid, NAL       
Streptomycin, STR       
Sulfisoxazole, FIS*       
Tetracycline, TET       
Trimethoprim, TMP       
 
*The antimicrobial which is mentioned in the CLSI M100 performance standard as a representative 
for the sulfonamides as regards acceptable limits for quality control strains (CLSI M100, Table 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
EU Community Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2011 
 
 
Appendix 4c, page 7 of 9 
Page 7 of 9 
DFVF- M00-06-001/24.10.2011 
 
TEST FORM                                                           
Strain Antimicrobial  Interpretation 
MIC-value (μg/ml) S / R 
Campylobacter 
EURL C-6.1 
 
C. jejuni 
 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-6.2 
 
C. jejuni 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-6.3 
 
C. jejuni 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C-6.4 
 
C. jejuni 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
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TEST FORM                                                           
 
Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
36 °C/48 hours 
 
42 °C/24 hours 
 
 
C. jejuni ATCC 33560 
 
Chloramphenicol             
Ciprofloxacin             
Erythromycin             
Nalidixic Acid             
Tetracycline             
 
 
  
For Agar dilution: 
 
 Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
 
C. jejuni ATCC 33560 
 
 
Ciprofloxacin       
 
Doxycycline        
 
Erythromycin        
 
Gentamicin       
Meropenem        
Nalidixic Acid        
Tetracycline       
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TEST FORM – genotypic characterisation                                                           
 
Genotypic characterisation of the test strains 
 
EURL GEN 3.X PCR-method used 
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
 
Comments:       
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
 
 
Manual from  Czech Collection of Microorganisms (CCM) 
 Masaryk University 
 Tvrdého 14 
 602 00 BRNO 
 Czech Republic 
 
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
Please note that:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue 
 Cultures may need at least one subculturing before they can be optimally used in experiments 
 Unopened ampoules should be kept in a dark and cool place! 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S21, January 2011 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A8, January 2009 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC 
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC 
validation) 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides 
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 Periodically perform colony counts to check the inoculum preparation procedure 
 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing. 
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DAILY MIC QC CHART 
 
Reference: CLSI M7-A8, page 44 
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WEEKLY MIC QC CHART 
 
 
Reference: CLSI M7-A8, page 45 
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Disk content and breakpoints used in daily routine (disk diffusion) - Salmonella
Antimicrobial Lab No Disk content 
(ug)
R <= (mm) I  = (mm) S >= (mm)
Ampicillin, AMP 38 10 13 14-16 17
Ampicillin, AMP 40 10 13
Ampicillin, AMP 57 25 13 14-16 17
Ampicillin, AMP 56 25 13 14-16 17
Cefotaxime, CTX 40 30 14
Cefotaxime, CTX 57 30 22 23-25 26
Cefotaxime, CTX 56 30 22 23-25 26
Cefotaxime, CTX 15 30 22 26
Cefotaxime, CTX 38 30 22 23-25 26
Ceftazidime, CAZ 40 30 14
Ceftazidime, CAZ 57 30 17 18-20 21
Ceftazidime, CAZ 56 30 17 18-20 21
Ceftazidime, CAZ 38 30 17 18-20 21
Ceftazidime, CAZ 15 30 20 26
Ceftiofur, XNL 40 30 14
Ceftiofur, XNL 56 30 17 18-20 21
Ceftiofur, XNL 15 30 17 21
Ceftiofur, XNL 38 30 17 18-20 21
Chloramphenicol, CHL 57 30 12 13-17 18
Chloramphenicol, CHL 56 30 12 13-17 18
Chloramphenicol, CHL 38 30 12 13-17 18
Chloramphenicol, CHL 40 30 12
Chloramphenicol, CHL 15 30 19 22
Ciprofloxacin, CIP 56 5 15 16-20 21
Ciprofloxacin, CIP 38 5 15 16-20 21
Ciprofloxacin, CIP 40 5 30
Ciprofloxacin, CIP 57 10 20 21-30 31
Gentamicin, GEN 56 10 12 13-14 15
Gentamicin, GEN 38 10 12 13-14 15
Gentamicin, GEN 40 10 12
Gentamicin, GEN 15 15 15 18
Gentamicin, GEN 57 30 12 13-14 15
Nalidixic acid, NAL 57 30 13 14-18 19
Nalidixic acid, NAL 56 30 13 14-18 19
Nalidixic acid, NAL 38 30 13 14-18 19
Nalidixic acid, NAL 40 30 13
Nalidixic acid, NAL 15 30 14 20
Streptomycin, STR 38 10 11 12-14 15
Streptomycin, STR 40 10 11
Streptomycin, STR 15 10  UI 12 15
Sulfamethoxazole, SMX 15 200 11 17
Sulfamethoxazole, SMX 56 250 12 13-16 17
Sulfamethoxazole, SMX 57 300 12 13-16 17
Sulfamethoxazole, SMX 38 300 12 13-16 17
Sulfamethoxazole, SMX 40 300 12
Tetracycline,TET 57 30 11 12-14 15
Tetracycline,TET 56 30 11 12-14 15
Tetracycline,TET 38 30 11 12-14 15
Tetracycline,TET 40 30 11
Tetracycline,TET 15 30 UI 16 19
Trimethoprim, TMP 57 5 10 11-15 16
Trimethoprim, TMP 56 5 10 11-15 16
Trimethoprim, TMP 38 5 10 11-15 16
Trimethoprim, TMP 40 5 10
Trimethoprim, TMP 15 5 11 16
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Test results from the reference strain E. coli ATCC 25922
Lab no. Antimicrobial Operator Value Low limit High limit Mark Method
1 Ampicillin, AMP = 4 2 8 1 MIC
1 Cefotaxime, CTX <= 0.125 0.03 0.125 1 MIC
1 Ceftiofur, XNL <= 0.5 0.25 1 1 MIC
1 Chloramphenicol, CHL = 4 2 8 1 MIC
1 Ciprofloxacin, CIP <= 0.015 0.004 0.016 1 MIC
1 Gentamicin, GEN = 2 0.25 1 0 MIC
1 Nalidixic acid, NAL <= 4 1 4 1 MIC
1 Tetracycline, TET <= 2 0.5 2 1 MIC
1 Trimethoprim, TMP <= 1 0.5 2 1 MIC
2 Ampicillin, AMP = 4 2 8 1 MIC
2 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
2 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
2 Chloramphenicol, CHL = 4 2 8 1 MIC
2 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
2 Gentamicin, GEN = 0.5 0.25 1 1 MIC
2 Nalidixic acid, NAL <= 4 1 4 1 MIC
2 Sulfisoxazole, FIS = 16 8 32 1 MIC
2 Tetracycline, TET <= 1 0.5 2 1 MIC
2 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
4 Ampicillin, AMP = 8 2 8 1 MIC
4 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
4 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC
4 Chloramphenicol, CHL = 4 2 8 1 MIC
4 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
4 Gentamicin, GEN = 1 0.25 1 1 MIC
4 Nalidixic acid, NAL = 4 1 4 1 MIC
4 Sulfisoxazole, FIS = 2 8 32 0 MIC
4 Tetracycline, TET = 0.5 0.5 2 1 MIC
4 Trimethoprim, TMP = 32 0.5 2 0 MIC
6 Ampicillin, AMP = 4 2 8 1 MIC
6 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
6 Ceftazidime, CAZ < 0.25 0.06 0.5 1 MIC
6 Chloramphenicol, CHL = 4 2 8 1 MIC
6 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
6 Gentamicin, GEN = 1 0.25 1 1 MIC
6 Nalidixic acid, NAL < 4 1 4 1 MIC
6 Tetracycline, TET < 1 0.5 2 1 MIC
6 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
9 Ampicillin, AMP = 4 2 8 1 MIC
9 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
9 Cefoxitin, FOX = 4 2 8 1 MIC
9 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC
9 Ceftiofur, XNL = 0.5 0.25 1 1 MIC
9 Chloramphenicol, CHL = 4 2 8 1 MIC
9 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
9 Gentamicin, GEN = 0.5 0.25 1 1 MIC
9 Imipenem, IMI = 0.12 0.06 0.25 1 MIC
9 Nalidixic acid, NAL = 4 1 4 1 MIC
9 Sulfisoxazole, FIS = 16 8 32 1 MIC
9 Tetracycline, TET = 1 0.5 2 1 MIC
9 Trimethoprim, TMP = 1 0.5 2 1 MIC
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11 Ampicillin, AMP = 4 2 8 1 MIC
11 Cefotaxime, CTX = 0.03 0.03 0.125 1 MIC
11 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
11 Chloramphenicol, CHL <= 2 2 8 1 MIC
11 Ciprofloxacin, CIP = 0.016 0.004 0.016 1 MIC
11 Gentamicin, GEN = 1 0.25 1 1 MIC
11 Nalidixic acid, NAL = 2 1 4 1 MIC
11 Sulfisoxazole, FIS = 16 8 32 1 MIC
11 Tetracycline, TET <= 1 0.5 2 1 MIC
11 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
12 Ampicillin, AMP = 4 2 8 1 MIC
12 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
12 Chloramphenicol, CHL = 4 2 8 1 MIC
12 Ciprofloxacin, CIP = 0.03 0.004 0.016 0 MIC
12 Gentamicin, GEN = 1 0.25 1 1 MIC
12 Nalidixic acid, NAL <= 2 1 4 1 MIC
12 Sulfisoxazole, FIS <= 8 8 32 1 MIC
12 Tetracycline, TET = 1 0.5 2 1 MIC
12 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
13 Ampicillin, AMP = 8 2 8 1 MIC
13 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
13 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
13 Chloramphenicol, CHL = 4 2 8 1 MIC
13 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
13 Gentamicin, GEN = 0.5 0.25 1 1 MIC
13 Nalidixic acid, NAL <= 4 1 4 1 MIC
13 Sulfisoxazole, FIS = 32 8 32 1 MIC
13 Tetracycline, TET <= 1 0.5 2 1 MIC
13 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
15 Cefotaxime, CTX = 35 29 35 1 DD
15 Cefoxitin, FOX = 27 23 29 1 DD
15 Ceftazidime, CAZ = 32 25 32 1 DD
15 Ceftiofur, XNL = 29 26 31 1 DD
15 Chloramphenicol, CHL = 26 21 27 1 DD
15 Gentamicin, GEN = 26 19 26 1 DD
15 Nalidixic acid, NAL = 24 22 28 1 DD
15 Tetracycline, TET = 25 18 25 1 DD
15 Trimethoprim, TMP = 25 21 28 1 DD
16 Ampicillin, AMP = 4 2 8 1 MIC
16 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
16 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC
16 Chloramphenicol, CHL = 8 2 8 1 MIC
16 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
16 Gentamicin, GEN = 1 0.25 1 1 MIC
16 Nalidixic acid, NAL = 2 1 4 1 MIC
16 Tetracycline, TET = 2 0.5 2 1 MIC
16 Trimethoprim, TMP = 2 0.5 2 1 MIC
17 Ampicillin, AMP = 4 2 8 1 MIC
17 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
17 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
17 Chloramphenicol, CHL = 4 2 8 1 MIC
17 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
17 Gentamicin, GEN = 0.5 0.25 1 1 MIC
17 Nalidixic acid, NAL <= 4 1 4 1 MIC
17 Sulfisoxazole, FIS = 32 8 32 1 MIC
17 Tetracycline, TET <= 1 0.5 2 1 MIC
17 Trimethoprim, TMP = 1 0.5 2 1 MIC
Appendix 6a, page 3 of 7
18 Ampicillin, AMP = 4 2 8 1 MIC
18 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC
18 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
18 Chloramphenicol, CHL = 4 2 8 1 MIC
18 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
18 Gentamicin, GEN = 0.5 0.25 1 1 MIC
18 Nalidixic acid, NAL <= 4 1 4 1 MIC
18 Sulfisoxazole, FIS = 32 8 32 1 MIC
18 Tetracycline, TET <= 1 0.5 2 1 MIC
18 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
19 Ampicillin, AMP = 4 2 8 1 MIC
19 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC
19 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
19 Chloramphenicol, CHL = 4 2 8 1 MIC
19 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
19 Gentamicin, GEN = 1 0.25 1 1 MIC
19 Nalidixic acid, NAL <= 4 1 4 1 MIC
19 Sulfisoxazole, FIS = 32 8 32 1 MIC
19 Tetracycline, TET <= 1 0.5 2 1 MIC
19 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
20 Ampicillin, AMP = 4 2 8 1 MIC
20 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
20 Cefoxitin, FOX <= 4 2 8 1 MIC
20 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
20 Chloramphenicol, CHL = 8 2 8 1 MIC
20 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
20 Gentamicin, GEN = 1 0.25 1 1 MIC
20 Imipenem, IMI <= 0.5 0.06 0.25 1 MIC
20 Nalidixic acid, NAL <= 4 1 4 1 MIC
20 Tetracycline, TET = 2 0.5 2 1 MIC
20 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
21 Ampicillin, AMP = 4 2 8 1 MIC
21 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC
21 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC
21 Chloramphenicol, CHL = 4 2 8 1 MIC
21 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
21 Gentamicin, GEN = 0.5 0.25 1 1 MIC
21 Nalidixic acid, NAL = 4 1 4 1 MIC
21 Sulfisoxazole, FIS = 16 8 32 1 MIC
21 Tetracycline, TET = 2 0.5 2 1 MIC
21 Trimethoprim, TMP = 1 0.5 2 1 MIC
22 Ampicillin, AMP = 8 2 8 1 MIC
22 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
22 Ceftazidime, CAZ < 0.25 0.06 0.5 1 MIC
22 Chloramphenicol, CHL = 4 2 8 1 MIC
22 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
22 Gentamicin, GEN = 1 0.25 1 1 MIC
22 Nalidixic acid, NAL < 4 1 4 1 MIC
22 Sulfisoxazole, FIS = 32 8 32 1 MIC
22 Tetracycline, TET = 2 0.5 2 1 MIC
22 Trimethoprim, TMP = 1 0.5 2 1 MIC
Appendix 6a, page 4 of 7
23 Ampicillin, AMP = 2 2 8 1 MIC
23 Cefotaxime, CTX < 0.25 0.03 0.125 1 MIC
23 Cefoxitin, FOX < 4 2 8 1 MIC
23 Ceftazidime, CAZ < 0.25 0.06 0.5 1 MIC
23 Ceftiofur, XNL = 0.5 0.25 1 1 MIC
23 Chloramphenicol, CHL = 4 2 8 1 MIC
23 Ciprofloxacin, CIP < 0.015 0.004 0.016 1 MIC
23 Gentamicin, GEN = 0.5 0.25 1 1 MIC
23 Imipenem, IMI < 0.5 0.06 0.25 1 MIC
23 Nalidixic acid, NAL = 2 1 4 1 MIC
23 Sulfisoxazole, FIS = 32 8 32 1 MIC
23 Tetracycline, TET < 4 0.5 2 1 MIC
25 Ampicillin, AMP = 4 2 8 1 MIC
25 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
25 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
25 Chloramphenicol, CHL = 8 2 8 1 MIC
25 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
25 Gentamicin, GEN = 1 0.25 1 1 MIC
25 Nalidixic acid, NAL <= 4 1 4 1 MIC
25 Sulfisoxazole, FIS <= 8 8 32 1 MIC
25 Tetracycline, TET = 2 0.5 2 1 MIC
25 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
26 Ampicillin, AMP = 4 2 8 1 MIC
26 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
26 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
26 Chloramphenicol, CHL = 4 2 8 1 MIC
26 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
26 Gentamicin, GEN = 0.5 0.25 1 1 MIC
26 Nalidixic acid, NAL <= 4 1 4 1 MIC
26 Tetracycline, TET <= 1 0.5 2 1 MIC
26 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
29 Ampicillin, AMP = 2 2 8 1 MIC
29 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC
29 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC
29 Chloramphenicol, CHL = 4 2 8 1 MIC
29 Ciprofloxacin, CIP = 0.016 0.004 0.016 1 MIC
29 Gentamicin, GEN = 0.5 0.25 1 1 MIC
29 Nalidixic acid, NAL = 2 1 4 1 MIC
29 Tetracycline, TET = 1 0.5 2 1 MIC
29 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
30 Ampicillin, AMP = 4 2 8 1 MIC
30 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC
30 Cefoxitin, FOX <= 4 2 8 1 MIC
30 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
30 Chloramphenicol, CHL = 4 2 8 1 MIC
30 Ciprofloxacin, CIP <= 0.008 0.004 0.016 1 MIC
30 Gentamicin, GEN = 1 0.25 1 1 MIC
30 Imipenem, IMI <= 0.5 0.06 0.25 1 MIC
30 Nalidixic acid, NAL <= 4 1 4 1 MIC
30 Sulfisoxazole, FIS = 16 8 32 1 MIC
30 Tetracycline, TET = 2 0.5 2 1 MIC
30 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
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32 Ampicillin, AMP = 4 2 8 1 MIC
32 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC
32 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
32 Chloramphenicol, CHL = 4 2 8 1 MIC
32 Ciprofloxacin, CIP <= 0.008 0.004 0.016 1 MIC
32 Gentamicin, GEN = 0.5 0.25 1 1 MIC
32 Nalidixic acid, NAL <= 4 1 4 1 MIC
32 Sulfisoxazole, FIS = 16 8 32 1 MIC
32 Tetracycline, TET <= 1 0.5 2 1 MIC
32 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
33 Ampicillin, AMP = 4 2 8 1 MIC
33 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
33 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC
33 Chloramphenicol, CHL = 4 2 8 1 MIC
33 Ciprofloxacin, CIP = 0.016 0.004 0.016 1 MIC
33 Gentamicin, GEN = 1 0.25 1 1 MIC
33 Nalidixic acid, NAL = 2 1 4 1 MIC
33 Sulfisoxazole, FIS = 32 8 32 1 MIC
33 Tetracycline, TET = 1 0.5 2 1 MIC
33 Trimethoprim, TMP = 1 0.5 2 1 MIC
34 Ampicillin, AMP = 4 2 8 1 MIC
34 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
34 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
34 Chloramphenicol, CHL = 4 2 8 1 MIC
34 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
34 Gentamicin, GEN = 0.5 0.25 1 1 MIC
34 Nalidixic acid, NAL <= 4 1 4 1 MIC
34 Sulfisoxazole, FIS <= 8 8 32 1 MIC
34 Tetracycline, TET <= 1 0.5 2 1 MIC
34 Trimethoprim, TMP = 1 0.5 2 1 MIC
36 Ampicillin, AMP = 2 2 8 1 MIC
36 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
36 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC
36 Chloramphenicol, CHL = 8 2 8 1 MIC
36 Ciprofloxacin, CIP = 0.03 0.004 0.016 0 MIC
36 Gentamicin, GEN = 0.5 0.25 1 1 MIC
36 Nalidixic acid, NAL = 2 1 4 1 MIC
36 Sulfisoxazole, FIS = 32 8 32 1 MIC
36 Tetracycline, TET <= 1 0.5 2 1 MIC
36 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
37 Ampicillin, AMP = 8 2 8 1 AGA
37 Cefotaxime, CTX <= 0.06 0.03 0.125 1 AGA
37 Chloramphenicol, CHL = 4 2 8 1 AGA
37 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 AGA
37 Gentamicin, GEN = 0.5 0.25 1 1 AGA
37 Nalidixic acid, NAL <= 2 1 4 1 AGA
37 Tetracycline, TET = 1 0.5 2 1 AGA
37 Trimethoprim, TMP = 0.5 0.5 2 1 AGA
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38 Ampicillin, AMP = 16 16 22 1 DD
38 Cefotaxime, CTX = 34 29 35 1 DD
38 Cefoxitin, FOX = 27 23 29 1 DD
38 Ceftazidime, CAZ = 30.7 25 32 1 DD
38 Ceftiofur, XNL = 27.5 26 31 1 DD
38 Chloramphenicol, CHL = 27.0 21 27 1 DD
38 Ciprofloxacin, CIP = 38.7 30 40 1 DD
38 Gentamicin, GEN = 26.0 19 26 1 DD
38 Imipenem, IMI = 29.7 26 32 1 DD
38 Nalidixic acid, NAL = 22.0 22 28 1 DD
38 Tetracycline, TET = 20.6 18 25 1 DD
38 Trimethoprim, TMP = 21.1 21 28 1 DD
39 Ampicillin, AMP = 2 2 8 1 MIC
39 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
39 Chloramphenicol, CHL = 4 2 8 1 MIC
39 Ciprofloxacin, CIP = 0.03 0.004 0.016 0 MIC
39 Gentamicin, GEN = 0.5 0.25 1 1 MIC
39 Nalidixic acid, NAL = 4 1 4 1 MIC
39 Sulfisoxazole, FIS = 32 8 32 1 MIC
39 Tetracycline, TET = 1 0.5 2 1 MIC
39 Trimethoprim, TMP = 1 0.5 2 1 MIC
40 Ampicillin, AMP = 18 16 22 1 DD
40 Cefotaxime, CTX = 31 29 35 1 DD
40 Cefoxitin, FOX = 27 23 29 1 DD
40 Ceftazidime, CAZ = 27 25 32 1 DD
40 Chloramphenicol, CHL = 24 21 27 1 DD
40 Ciprofloxacin, CIP = 35 30 40 1 DD
40 Gentamicin, GEN = 25 19 26 1 DD
40 Imipenem, IMI = 30 26 32 1 DD
40 Nalidixic acid, NAL = 24 22 28 1 DD
40 Tetracycline, TET = 23 18 25 1 DD
40 Trimethoprim, TMP = 27 21 28 1 DD
41 Ampicillin, AMP = 4 2 8 1 MIC
41 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC
41 Cefoxitin, FOX = 4 2 8 1 MIC
41 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC
41 Ceftiofur, XNL = 0.5 0.25 1 1 MIC
41 Chloramphenicol, CHL = 8 2 8 1 MIC
41 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
41 Gentamicin, GEN = 0.5 0.25 1 1 MIC
41 Nalidixic acid, NAL = 2 1 4 1 MIC
41 Tetracycline, TET = 1 0.5 2 1 MIC
41 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
42 Ampicillin, AMP = 4 2 8 1 MIC
42 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
42 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
42 Chloramphenicol, CHL = 4 2 8 1 MIC
42 Ciprofloxacin, CIP = 0.05 0.004 0.016 0 MIC
42 Gentamicin, GEN = 0.5 0.25 1 1 MIC
42 Nalidixic acid, NAL <= 4 1 4 1 MIC
42 Sulfisoxazole, FIS = 32 8 32 1 MIC
42 Tetracycline, TET <= 1 0.5 2 1 MIC
42 Trimethoprim, TMP = 1 0.5 2 1 MIC
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56 Ampicillin, AMP = 22 16 22 1 DD
56 Cefotaxime, CTX = 33 29 35 1 DD
56 Cefoxitin, FOX = 25 23 29 1 DD
56 Ceftazidime, CAZ = 29 25 32 1 DD
56 Ceftiofur, XNL = 26 26 31 1 DD
56 Chloramphenicol, CHL = 25 21 27 1 DD
56 Ciprofloxacin, CIP = 32 30 40 1 DD
56 Gentamicin, GEN = 21 19 26 1 DD
56 Nalidixic acid, NAL = 26 22 28 1 DD
56 Sulfisoxazole, FIS = 16 15 23 1 DD
56 Tetracycline, TET = 24 18 25 1 DD
56 Trimethoprim, TMP = 21 21 28 1 DD
57 Ampicillin, AMP = 20 16 22 1 DD
57 Cefotaxime, CTX = 30 29 35 1 DD
57 Cefoxitin, FOX = 28 23 29 1 DD
57 Ceftazidime, CAZ = 26 25 32 1 DD
57 Ceftiofur, XNL = 24 26 31 0 DD
57 Chloramphenicol, CHL = 25 21 27 1 DD
57 Ciprofloxacin, CIP = 35 30 40 1 DD
57 Gentamicin, GEN = 25 19 26 1 DD
57 Nalidixic acid, NAL = 26 22 28 1 DD
57 Sulfisoxazole, FIS = 21 15 23 1 DD
57 Tetracycline, TET = 23 18 25 1 DD
57 Trimethoprim, TMP = 24 21 28 1 DD
58 Ampicillin, AMP = 8 2 8 1 MIC
58 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
58 Cefoxitin, FOX <= 4 2 8 1 MIC
58 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
58 Ceftiofur, XNL = 0.5 0.25 1 1 MIC
58 Chloramphenicol, CHL = 8 2 8 1 MIC
58 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
58 Gentamicin, GEN = 1 0.25 1 1 MIC
58 Imipenem, IMI <= 0.5 0.06 0.25 1 MIC
58 Nalidixic acid, NAL <= 4 1 4 1 MIC
58 Sulfisoxazole, FIS = 32 8 32 1 MIC
58 Tetracycline, TET <= 1 0.5 2 1 MIC
58 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
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Test results from the reference strain C. jejuni ATCC 33560
Lab no. Antimicrobial Operator Value Low limit High limit Mark Method 36-37ºC/48h 42ºC/24h
1 Chloramphenicol, CHL = 8 1 8 1 MIC X
1 Ciprofloxacin, CIP = 0.25 0.06 0.25 1 MIC X
1 Erythromycin, ERY = 2 0.5 2 1 MIC X
1 Gentamicin, GEN = 0.5 0.5 2 1 MIC X
1 Nalidixic acid, NAL = 8 4 16 1 MIC X
1 Tetracycline, TET = 2 0.25 2 1 MIC X
2 Chloramphenicol, CHL = 4 1 8 1 MIC X
2 Ciprofloxacin, CIP = 0.25 0.06 0.25 1 MIC X
2 Erythromycin, ERY = 1 0.5 2 1 MIC X
2 Gentamicin, GEN = 0.5 0.5 2 1 MIC X
2 Nalidixic acid, NAL = 8 4 16 1 MIC X
2 Tetracycline, TET = 2 0.25 2 1 MIC X
4 Chloramphenicol, CHL = 4 1 8 1 MIC X
4 Ciprofloxacin, CIP = 0.25 0.06 0.25 1 MIC X
4 Erythromycin, ERY = 1 0.5 2 1 MIC X
4 Gentamicin, GEN = 1 0.5 2 1 MIC X
4 Nalidixic acid, NAL = 8 4 16 1 MIC X
4 Tetracycline, TET = 1 0.25 2 1 MIC X
6 Chloramphenicol, CHL < 2 1 4 1 MIC X
6 Ciprofloxacin, CIP < 0.06 0.03 0.125 1 MIC X
6 Erythromycin, ERY < 0.5 0.25 2 1 MIC X
6 Gentamicin, GEN = 1 0.25 2 1 MIC X
6 Nalidixic acid, NAL = 4 4 16 1 MIC X
6 Tetracycline, TET = 0.5 0.25 1 1 MIC X
9 Chloramphenicol, CHL = 4 1 8 1 MIC X
9 Ciprofloxacin, CIP = 0.12 0.06 0.25 1 MIC X
9 Erythromycin, ERY = 1 0.5 2 1 MIC X
9 Gentamicin, GEN = 1 0.5 2 1 MIC X
9 Nalidixic acid, NAL = 8 4 16 1 MIC X
9 Tetracycline, TET = 0.5 0.25 2 1 MIC X
11 Ciprofloxacin, CIP = 0.25 0.06 0.25 1 MIC X
11 Erythromycin, ERY = 1 0.5 2 1 MIC X
11 Gentamicin, GEN = 0.5 0.5 2 1 MIC X
11 Nalidixic acid, NAL = 8 4 16 1 MIC X
11 Tetracycline, TET = 1 0.25 2 1 MIC X
12 Ciprofloxacin, CIP = 0.25 0.06 0.25 1 MIC X
12 Erythromycin, ERY = 1 0.5 2 1 MIC X
12 Gentamicin, GEN = 1 0.5 2 1 MIC X
12 Nalidixic acid, NAL = 16 4 16 1 MIC X
12 Tetracycline, TET = 1 0.25 2 1 MIC X
14 Chloramphenicol, CHL <= 2 1 4 1 MIC X
14 Ciprofloxacin, CIP = 0.125 0.03 0.125 1 MIC X
14 Erythromycin, ERY <= 0.5 0.25 2 1 MIC X
14 Gentamicin, GEN = 1 0.25 2 1 MIC X
14 Nalidixic acid, NAL = 4 4 16 1 MIC X
14 Tetracycline, TET = 0.5 0.25 1 1 MIC X
17 Chloramphenicol, CHL = 4 1 8 1 MIC X
17 Ciprofloxacin, CIP = 0.25 0.06 0.25 1 MIC X
17 Erythromycin, ERY = 2 0.5 2 1 MIC X
17 Gentamicin, GEN = 1 0.5 2 1 MIC X
17 Nalidixic acid, NAL = 8 4 16 1 MIC X
17 Tetracycline, TET = 1 0.25 2 1 MIC X
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19 Chloramphenicol, CHL <= 2 1 4 1 MIC X
19 Ciprofloxacin, CIP = 0.12 0.03 0.125 1 MIC X
19 Erythromycin, ERY <= 0.5 0.25 2 1 MIC X
19 Gentamicin, GEN = 1 0.25 2 1 MIC X
19 Nalidixic acid, NAL = 8 4 16 1 MIC X
19 Tetracycline, TET = 1 0.25 1 1 MIC X
20 Chloramphenicol, CHL <= 2 1 8 1 MIC X
20 Ciprofloxacin, CIP = 0.12 0.06 0.25 1 MIC X
20 Erythromycin, ERY <= 0.5 0.5 2 1 MIC X
20 Gentamicin, GEN = 0.5 0.5 2 1 MIC X
20 Nalidixic acid, NAL = 4 4 16 1 MIC X
20 Tetracycline, TET = 0.5 0.25 2 1 MIC X
21 Chloramphenicol, CHL <= 2 1 4 1 MIC X
21 Ciprofloxacin, CIP = 0.12 0.03 0.125 1 MIC X
21 Erythromycin, ERY <= 0.5 0.25 2 1 MIC X
21 Gentamicin, GEN = 0.12 0.25 2 0 MIC X
21 Nalidixic acid, NAL = 4 4 16 1 MIC X
21 Tetracycline, TET = 0.25 0.25 1 1 MIC X
22 Chloramphenicol, CHL = 4 1 8 1 MIC X
22 Ciprofloxacin, CIP = 0.12 0.06 0.25 1 MIC X
22 Erythromycin, ERY = 1 0.5 2 1 MIC X
22 Nalidixic acid, NAL = 8 4 16 1 MIC X
22 Tetracycline, TET = 1 0.25 2 1 MIC X
23 Chloramphenicol, CHL < 2 1 4 1 MIC X
23 Ciprofloxacin, CIP = 0.12 0.03 0.125 1 MIC X
23 Erythromycin, ERY < 0.5 0.25 2 1 MIC X
23 Gentamicin, GEN = 1 0.25 2 1 MIC X
23 Nalidixic acid, NAL = 8 4 16 1 MIC X
23 Tetracycline, TET = 1 0.25 1 1 MIC X
25 Chloramphenicol, CHL = 4 1 8 1 MIC X
25 Ciprofloxacin, CIP <= 0.12 0.06 0.25 1 MIC X
25 Erythromycin, ERY = 2 0.5 2 1 MIC X
25 Gentamicin, GEN = 0.5 0.5 2 1 MIC X
25 Nalidixic acid, NAL = 8 4 16 1 MIC X
25 Tetracycline, TET = 2 0.25 2 1 MIC X
26 Chloramphenicol, CHL <= 2 1 8 1 MIC X
26 Ciprofloxacin, CIP = 0.12 0.06 0.25 1 MIC X
26 Erythromycin, ERY <= 0.5 0.5 2 1 MIC X
26 Gentamicin, GEN = 1 0.5 2 1 MIC X
26 Nalidixic acid, NAL = 8 4 16 1 MIC X
26 Tetracycline, TET = 1 0.25 2 1 MIC X
29 Ciprofloxacin, CIP = 4 0.06 0.25 0 MIC X
29 Erythromycin, ERY = 0.25 0.5 2 0 MIC X
29 Gentamicin, GEN = 2 0.5 2 1 MIC X
29 Nalidixic acid, NAL = 16 4 16 1 MIC X
29 Tetracycline, TET = 2 0.25 2 1 MIC X
30 Chloramphenicol, CHL = 4 1 8 1 MIC X
30 Ciprofloxacin, CIP = 0.25 0.06 0.25 1 MIC X
30 Erythromycin, ERY = 1 0.5 2 1 MIC X
30 Gentamicin, GEN = 1 0.5 2 1 MIC X
30 Nalidixic acid, NAL = 8 4 16 1 MIC X
30 Tetracycline, TET = 2 0.25 2 1 MIC X
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32 Chloramphenicol, CHL <= 2 1 8 1 MIC X
32 Ciprofloxacin, CIP = 0.125 0.06 0.25 1 MIC X
32 Erythromycin, ERY <= 0.5 0.5 2 1 MIC X
32 Gentamicin, GEN = 1 0.5 2 1 MIC X
32 Nalidixic acid, NAL = 8 4 16 1 MIC X
32 Tetracycline, TET = 1 0.25 2 1 MIC X
33 Ciprofloxacin, CIP = 0.12 0.06 0.25 1 MIC X
33 Erythromycin, ERY <= 0.5 0.5 2 1 MIC X
33 Gentamicin, GEN = 0.5 0.5 2 1 MIC X
33 Nalidixic acid, NAL = 8 4 16 1 MIC X
33 Tetracycline, TET = 0.5 0.25 2 1 MIC X
34 Chloramphenicol, CHL = 2 1 8 1 MIC X
34 Ciprofloxacin, CIP = 0.12 0.06 0.25 1 MIC X
34 Erythromycin, ERY = 0.5 0.5 2 1 MIC X
34 Gentamicin, GEN = 1 0.5 2 1 MIC X
34 Nalidixic acid, NAL = 8 4 16 1 MIC X
34 Tetracycline, TET = 1 0.25 2 1 MIC X
36 Ciprofloxacin, CIP = 0.25 0.06 0.25 1 MIC X
36 Erythromycin, ERY <= 0.5 0.5 2 1 MIC X
36 Gentamicin, GEN = 1 0.5 2 1 MIC X
36 Nalidixic acid, NAL = 8 4 16 1 MIC X
36 Tetracycline, TET = 1 0.25 2 1 MIC X
37 Ciprofloxacin, CIP = 0.25 0.12 1 1 AGA X
37 Erythromycin, ERY = 2 1 8 1 AGA X
37 Gentamicin, GEN = 1 0.5 2 1 AGA X
39 Ciprofloxacin, CIP = 0.25 0.06 0.25 1 MIC X
39 Erythromycin, ERY = 2 0.5 2 1 MIC X
39 Gentamicin, GEN = 1 0.5 2 1 MIC X
39 Nalidixic acid, NAL = 4 4 16 1 MIC X
39 Tetracycline, TET = 1 0.25 2 1 MIC X
40 Chloramphenicol, CHL = 2 1 4 1 MIC X
40 Ciprofloxacin, CIP = 0.12 0.03 0.125 1 MIC X
40 Erythromycin, ERY = 2 0.25 2 1 MIC X
40 Gentamicin, GEN = 0.5 0.25 2 1 MIC X
40 Nalidixic acid, NAL = 4 4 16 1 MIC X
40 Tetracycline, TET = 0.5 0.25 1 1 MIC X
41 Chloramphenicol, CHL = 2 1 4 1 MIC X
41 Ciprofloxacin, CIP = 0.06 0.03 0.125 1 MIC X
41 Erythromycin, ERY = 0.5 0.25 2 1 MIC X
41 Gentamicin, GEN = 1 0.25 2 1 MIC X
41 Nalidixic acid, NAL = 4 4 16 1 MIC X
41 Tetracycline, TET = 0.5 0.25 1 1 MIC X
42 Chloramphenicol, CHL <= 2 MIC
42 Ciprofloxacin, CIP = 0.12 MIC
42 Erythromycin, ERY <= 0.5 MIC
42 Gentamicin, GEN <= 0.12 MIC
42 Nalidixic acid, NAL = 8 MIC
42 Tetracycline, TET = 4 MIC
44 Ciprofloxacin, CIP < 1 0.12 1 1 AGA X
44 Erythromycin, ERY < 4 1 8 1 AGA X
44 Gentamicin, GEN < 2 0.5 2 1 AGA X
58 Chloramphenicol, CHL = 4 1 8 1 MIC X
58 Ciprofloxacin, CIP = 0.25 0.06 0.25 1 MIC X
58 Erythromycin, ERY = 1 0.5 2 1 MIC X
58 Gentamicin, GEN = 1 0.5 2 1 MIC X
58 Nalidixic acid, NAL = 8 4 16 1 MIC X
58 Tetracycline, TET = 1 0.25 2 1 MIC X
37°C 24 h 
37°C 24 h 
37°C 24 h 
37°C 24 h 
37°C 24 h 
37°C 24 h 
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QC ranges for reference strains
Antimicrobial
Ampicillin, AMP
Cefotaxime, CTX
Cefoxitin, FOX
Ceftazidime, CAZ
Ceftiofur, XNL 
Chloramphenicol, CHL
Ciprofloxacin, CIP
Gentamicin, GEN
Imipenem, IMI
Nalidixic acid, NAL
Sulfisoxazole, FIS
Tetracycline, TET
Trimethoprim, TMP
E-test ranges are according to AB-Biodisk
Antimicrobial Microbroth                
(36-37°C/48h)
Microbroth 
(42°C/24h)
Agar dilution     
(36-37°C/48h)
Agar dilution     
(42°C/24h)
Chloramphenicol, CHL 1-8 1-4 None None
Ciprofloxacin, CIP 0.06-0.25 0.03-0.12 0.12-1 0.06-0.5
Erythromycin, ERY 0.5-2 0.25-2 1-8 1-4
Gentamicin, GEN 0.5-2 0.25-2 0.5-2 0.5-4
Nalidixic acid, NAL 4-16 4-16 None None
Tetracycline, TET 0.25-2 0.25-1 None None
0.5-2
Ranges are according to CLSI (M31-A3) 
Campylobacter jejuni ATCC 33560
E. coli ATCC 25922
DD (disc content)
16-22 (10µg)
29-35 (30µg)
23-29 (30µg)
25-32 (30µg)
26-31 (30µg)
21-27 (30µg)
21-28 (5µg)
MIC ranges and disc diffusion ranges are according to CLSI M100 S22 with the following exceptions: 
The range for ceftiofur is according to M31-A3 and the range for ciprofloxacin is extended to include 
0.016 as well.
22-28 (30µg)
15-23 (250/300µg)
30-40 (5µg)
0.5-2
19-26 (10µg)
26-32 (10µg)
18-25 (30µg)
MIC
2-8
0.03-0.12
2-8
0.06-0.5
0.25-1
2-8
0.004-0.016
0.25-1
0.06-0.25
1-4
8-32
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Salmonella - expected and obtained interpretation
Antimicrobial Strain Expected % R % S No. 
correct
No. 
incorrect
EURL S-7.1 R 100% 0% 34 0
EURL S-7.2 R 100% 0% 34 0
EURL S-7.3 R 100% 0% 34 0
EURL S-7.4 R 100% 0% 34 0
EURL S-7.5 S 0% 100% 34 0
EURL S-7.6 R 100% 0% 34 0
EURL S-7.7 S 0% 100% 34 0
EURL S-7.8 S 0% 100% 34 0
EURL S-7.1 R 97% 3% 34 1
EURL S-7.2 R 100% 0% 35 0
EURL S-7.3 R 100% 0% 35 0
EURL S-7.4 S 3% 97% 34 1
EURL S-7.5 S 0% 100% 35 0
EURL S-7.6 R 100% 0% 35 0
EURL S-7.7 S 0% 100% 35 0
EURL S-7.8 S 0% 100% 35 0
EURL S-7.1 R 100% 0% 31 0
EURL S-7.2 R 100% 0% 31 0
EURL S-7.3 S 6% 94% 29 2
EURL S-7.4 S 0% 100% 30 0
EURL S-7.5 S 0% 100% 30 0
EURL S-7.6 R 100% 0% 31 0
EURL S-7.7 S 0% 100% 30 0
EURL S-7.8 S 0% 100% 30 0
EURL S-7.1 R 100% 0% 13 0
EURL S-7.2 R 100% 0% 11 0
EURL S-7.3 R 89% 11% 8 1
EURL S-7.4 S 0% 100% 10 0
EURL S-7.5 S 0% 100% 12 0
EURL S-7.6 R 100% 0% 10 0
EURL S-7.7 S 0% 100% 10 0
EURL S-7.8 S 0% 100% 10 0
EURL S-7.1 R 97% 3% 34 1
EURL S-7.2 R 100% 0% 35 0
EURL S-7.3 S 3% 97% 34 1
EURL S-7.4 S 0% 100% 35 0
EURL S-7.5 S 0% 100% 35 0
EURL S-7.6 S 0% 100% 35 0
EURL S-7.7 S 0% 100% 35 0
EURL S-7.8 R 100% 0% 35 0
EURL S-7.1 R 100% 0% 34 0
EURL S-7.2 R 100% 0% 34 0
EURL S-7.3 R 97% 3% 33 1
EURL S-7.4 R 97% 3% 33 1
EURL S-7.5 S 0% 100% 34 0
EURL S-7.6 S 3% 97% 33 1
EURL S-7.7 R 97% 3% 33 1
EURL S-7.8 R 91% 9% 30 3
Ampicillin, AMP
Ciprofloxacin, CIP
Chloramphenicol, CHL
Ceftiofur, XNL
Ceftazidime, CAZ
Cefotaxime, CTX
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EURL S-7.1 R 97% 3% 34 1
EURL S-7.2 R 100% 0% 35 0
EURL S-7.3 S 3% 97% 34 1
EURL S-7.4 S 0% 100% 35 0
EURL S-7.5 S 0% 100% 35 0
EURL S-7.6 S 0% 100% 35 0
EURL S-7.7 S 0% 100% 35 0
EURL S-7.8 S 0% 100% 35 0
EURL S-7.1 R 97% 3% 34 1
EURL S-7.2 R 100% 0% 35 0
EURL S-7.3 R 100% 0% 35 0
EURL S-7.4 R 100% 0% 35 0
EURL S-7.5 S 0% 100% 35 0
EURL S-7.6 S 0% 100% 35 0
EURL S-7.7 R 100% 0% 35 0
EURL S-7.8 S 6% 94% 33 2
EURL S-7.1 R 100% 0% 35 0
EURL S-7.2 R 100% 0% 35 0
EURL S-7.3 S 6% 94% 33 2
EURL S-7.4 R 97% 3% 34 1
EURL S-7.5 S 3% 97% 34 1
EURL S-7.6 S 3% 97% 34 1
EURL S-7.7 R 100% 0% 35 0
EURL S-7.8 S 3% 97% 34 1
EURL S-7.1 R 100% 0% 35 0
EURL S-7.2 R 100% 0% 35 0
EURL S-7.3 R 100% 0% 35 0
EURL S-7.4 S 0% 100% 35 0
EURL S-7.5 S 0% 100% 35 0
EURL S-7.6 S 0% 100% 35 0
EURL S-7.7 R 100% 0% 35 0
EURL S-7.8 S 3% 97% 34 1
EURL S-7.1 R 97% 3% 33 1
EURL S-7.2 R 100% 0% 34 0
EURL S-7.3 S 3% 97% 33 1
EURL S-7.4 R 100% 0% 34 0
EURL S-7.5 S 0% 100% 34 0
EURL S-7.6 S 0% 100% 34 0
EURL S-7.7 R 97% 3% 32 1
EURL S-7.8 S 0% 100% 34 0
Nalidixic acid, NAL
Trimethoprim, TMP
Tetracycline, TET
Sulphonamides, SMX
Gentamicin, GEN
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Campylobacter  - expected and obtained interpretation
 
Antimicrobial Strain Expected % R % S No. correct
No. 
incorrect
EURL C-7.1 S 0% 100% 23 0
EURL C-7.2 S 0% 100% 23 0
EURL C-7.3 S 0% 100% 23 0
EURL C-7.4 S 0% 100% 23 0
EURL C-7.5 S 0% 100% 23 0
EURL C-7.6 S 0% 100% 23 0
EURL C-7.7 S 0% 100% 23 0
EURL C-7.8 S 0% 100% 23 0
EURL C-7.1 S 0% 100% 29 0
EURL C-7.2 S 0% 100% 29 0
EURL C-7.3 S 0% 100% 29 0
EURL C-7.4 R 97% 3% 28 1
EURL C-7.5 R 97% 3% 28 1
EURL C-7.6 R 97% 3% 28 1
EURL C-7.7 S 3% 97% 28 1
EURL C-7.8 R 93% 7% 27 2
EURL C-7.1 R 100% 0% 29 0
EURL C-7.2 R 100% 0% 29 0
EURL C-7.3 S 3% 97% 28 1
EURL C-7.4 S 14% 86% 25 4
EURL C-7.5 S 3% 97% 28 1
EURL C-7.6 R 100% 0% 29 0
EURL C-7.7 S 3% 97% 28 1
EURL C-7.8 S 0% 100% 29 0
EURL C-7.1 S 0% 100% 29 0
EURL C-7.2 S 0% 100% 29 0
EURL C-7.3 S 0% 100% 29 0
EURL C-7.4 S 0% 100% 29 0
EURL C-7.5 S 0% 100% 29 0
EURL C-7.6 R 100% 0% 29 0
EURL C-7.7 S 0% 100% 29 0
EURL C-7.8 S 0% 100% 29 0
EURL C-7.1 S 3% 97% 28 1
EURL C-7.2 S 4% 96% 27 1
EURL C-7.3 S 3% 97% 28 1
EURL C-7.4 R 97% 3% 28 1
EURL C-7.5 R 97% 3% 28 1
EURL C-7.6 R 97% 3% 28 1
EURL C-7.7 S 0% 100% 29 0
EURL C-7.8 R 93% 7% 27 2
EURL C-7.1 S 7% 93% 27 2
EURL C-7.2 S 7% 93% 27 2
EURL C-7.3 S 3% 97% 28 1
EURL C-7.4 R 93% 7% 27 2
EURL C-7.5 R 97% 3% 28 1
EURL C-7.6 R 100% 0% 29 0
EURL C-7.7 S 0% 100% 29 0
EURL C-7.8 S 0% 100% 29 0
EURL C-7.1* S 29% 71% 20 8
EURL C-7.2 R 100% 0% 29 0
EURL C-7.3 S 3% 97% 28 1
EURL C-7.4 R 100% 0% 29 0
EURL C-7.5 S 4% 96% 27 1
EURL C-7.6 R 100% 0% 29 0
EURL C-7.7 R 97% 3% 28 1
EURL C-7.8 R 97% 3% 28 1
*Strain/antimicrobial-combination excluded from the evaluation
Tetracycline, TET
Chloramphenicol, CHL
Streptomycin, STR
Nalidixic acid, NAL
Gentamicin, GEN
Erythromycin, ERY
Ciprofloxacin, CIP
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Deviations - Salmonella
Lab no. Strain Antimicrobial Obtained 
interpretation
Obtained 
value
Expected 
interpretation
Expected 
MIC
Method 
used
1 EURL S-7.6 Confirmed AmpC No Yes MIC
4 EURL S-7.6 Confirmed AmpC No Yes MIC
6 EURL S-7.6 Confirmed AmpC No Yes MIC
6 EURL S-7.8 Nalidixic acid, NAL R >64 S = 4 MIC
6 EURL S-7.8 Tetracycline, TET R <=32 S <= 2 MIC
9 EURL S-7.6 Confirmed AmpC No Yes MIC
11 EURL S-7.6 Confirmed AmpC No Yes MIC
12 EURL S-7.2 Confirmed AmpC Yes No MIC
12 EURL S-7.2 Confirmed ESBL No Yes MIC
12 EURL S-7.3 Confirmed ESBL No Yes MIC
12 EURL S-7.4 Sulfamethoxazole, SMX S 256 R > 1024 MIC
15 EURL S-7.4 Confirmed AmpC Yes No DD
15 EURL S-7.6 Confirmed AmpC No Yes DD
15 EURL S-7.6 Confirmed ESBL Yes No DD
16 EURL S-7.1 Confirmed AmpC Yes No MIC
16 EURL S-7.1 Confirmed ESBL No Yes MIC
18 EURL S-7.4 Confirmed AmpC Yes No MIC
19 EURL S-7.1 Confirmed AmpC Yes No MIC
19 EURL S-7.6 Confirmed AmpC No Yes MIC
19 EURL S-7.6 Confirmed ESBL Yes No MIC
20 EURL S-7.6 Confirmed AmpC No Yes MIC
22 EURL S-7.3 Ceftazidime, CAZ R 1 S = 1 MIC
22 EURL S-7.6 Confirmed AmpC No Yes MIC
22 EURL S-7.6 Confirmed ESBL Yes No MIC
23 EURL S-7.6 Confirmed AmpC No Yes MIC
25 EURL S-7.6 Confirmed AmpC No Yes MIC
26 EURL S-7.6 Confirmed AmpC No Yes MIC
29 EURL S-7.3 Ceftiofur, XNL S 19mm R > 8 MIC
29 EURL S-7.3 Confirmed ESBL No Yes MIC
29 EURL S-7.8 Ciprofloxacin, CIP S 0.5 R = 0.5 MIC
30 EURL S-7.6 Confirmed AmpC No Yes MIC
32 EURL S-7.6 Confirmed AmpC No Yes MIC
32 EURL S-7.6 Confirmed MBL Yes No MIC
34 EURL S-7.6 Confirmed AmpC No Yes MIC
37 EURL S-7.6 Confirmed AmpC No Yes AGA
38 EURL S-7.1 Confirmed AmpC Yes No DD
38 EURL S-7.2 Confirmed AmpC Yes No DD
38 EURL S-7.6 Confirmed AmpC No Yes DD
38 EURL S-7.6 Confirmed ESBL Yes No DD
38 EURL S-7.8 Nalidixic acid, NAL R 10.8 S = 4 DD
39 EURL S-7.6 Confirmed AmpC No Yes MIC
40 EURL S-7.1 Gentamicin, GEN S 14 R > 16 DD
41 EURL S-7.1 Confirmed ESBL No Yes MIC
41 EURL S-7.6 Ciprofloxacin, CIP R 0.25 S <= 0.015 MIC
41 EURL S-7.6 Confirmed AmpC No Yes MIC
41 EURL S-7.6 Confirmed ESBL Yes No MIC
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42 EURL S-7.3 Ceftazidime, CAZ R >16 S = 1 MIC
42 EURL S-7.3 Chloramphenicol, CHL R >64 S = 4 MIC
42 EURL S-7.3 Gentamicin, GEN R >32 S <= 0.5 MIC
42 EURL S-7.3 Sulfamethoxazole, SMX R >1024 S = 32 MIC
42 EURL S-7.3 Trimethoprim, TMP R >32 S <= 1 MIC
44 EURL S-7.1 Cefotaxime, CTX S <1 R > 64 AGA
44 EURL S-7.1 Chloramphenicol, CHL S <8 R > 64 AGA
44 EURL S-7.1 Confirmed ESBL No Yes AGA
44 EURL S-7.1 Nalidixic acid, NAL S <16 R > 64 AGA
44 EURL S-7.1 Trimethoprim, TMP S <2 R > 32 AGA
44 EURL S-7.2 Confirmed ESBL No Yes AGA
44 EURL S-7.3 Confirmed ESBL No Yes AGA
44 EURL S-7.4 Cefotaxime, CTX R >1 S = 0.25 AGA
44 EURL S-7.6 Confirmed AmpC No Yes AGA
56 EURL S-7.1 Confirmed AmpC Yes No DD
56 EURL S-7.1 Confirmed ESBL No Yes DD
56 EURL S-7.3 Sulfamethoxazole, SMX R 6 S = 32 DD
56 EURL S-7.5 Sulfamethoxazole, SMX R 6 S = 64 DD
56 EURL S-7.6 Confirmed AmpC No Yes DD
56 EURL S-7.6 Sulfamethoxazole, SMX R 6 S = 64 DD
56 EURL S-7.8 Ciprofloxacin, CIP S 28 R = 0.5 DD
56 EURL S-7.8 Sulfamethoxazole, SMX R 6 S = 32 DD
57 EURL S-7.1 Confirmed ESBL No Yes DD
57 EURL S-7.2 Confirmed ESBL No Yes DD
57 EURL S-7.3 Ciprofloxacin, CIP S 28 R = 0.5 DD
57 EURL S-7.3 Confirmed ESBL No Yes DD
57 EURL S-7.4 Ciprofloxacin, CIP S 27 R = 0.5 DD
57 EURL S-7.6 Confirmed AmpC No Yes DD
57 EURL S-7.7 Ciprofloxacin, CIP S 30 R = 0.25 DD
57 EURL S-7.7 Trimethoprim, TMP S 27 R > 32 DD
57 EURL S-7.8 Ciprofloxacin, CIP S 31 R = 0.5 DD
58 EURL S-7.6 Confirmed AmpC No Yes MIC
AGA Agar dilution
DD Disk diffusion
ET E-test
MIC Microbroth dilution
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Deviations - Campylobacter
Lab no. Strain Antimicrobial Obtained 
interpretation
Obtained 
value
Expected 
interpretation
Expected 
MIC
Method 
used
1 EURL C-7.4 Erythromycin, ERY R 16.0 S = 8 MIC
29 EURL C-7.3 Erythromycin, ERY R 64 S = 1 MIC
29 EURL C-7.3 Nalidixic acid, NAL R 64 S = 4 MIC
29 EURL C-7.3 Tetracycline, TET R 4 S = 0.5 MIC
29 EURL C-7.7 Tetracycline, TET S <0.12 R = 32 MIC
32 EURL C-7.5 Ciprofloxacin, CIP S <=0.125 R = 8 MIC
32 EURL C-7.5 Nalidixic acid, NAL S <=8 R > 64 MIC
32 EURL C-7.5 Streptomycin, STR S <=2 R > 16 MIC
32 EURL C-7.7 Ciprofloxacin, CIP R <=4 S = 0.12 MIC
36 EURL C-7.1 Streptomycin, STR R 8 S = 2 MIC
36 EURL C-7.2 Streptomycin, STR R 4 S = 4 MIC
36 EURL C-7.3 Streptomycin, STR R 4 S <= 1 MIC
36 EURL C-7.4 Erythromycin, ERY R 8 S = 8 MIC
37 EURL C-7.4 Erythromycin, ERY R 16 S = 8 AGA
39 EURL C-7.6 Nalidixic acid, NAL S 1 R > 64 MIC
39 EURL C-7.8 Ciprofloxacin, CIP S <=0.06 R > 4 MIC
39 EURL C-7.8 Nalidixic acid, NAL S 2 R > 64 MIC
39 EURL C-7.8 Tetracycline, TET S <=0.12 R = 32 MIC
40 EURL C-7.1 Streptomycin, STR R 16 S = 2 MIC
40 EURL C-7.2 Streptomycin, STR R 16 S = 4 MIC
40 EURL C-7.4 Ciprofloxacin, CIP S 0.06 R = 32 MIC
40 EURL C-7.4 Erythromycin, ERY R 32 S = 8 MIC
40 EURL C-7.4 Nalidixic acid, NAL S 2 R > 64 MIC
40 EURL C-7.4 Streptomycin, STR S 2 R > 16 MIC
44 EURL C-7.1 Nalidixic acid, NAL R >16,<32 S = 8 AGA
44 EURL C-7.2 Nalidixic acid, NAL R >16, <32 S = 8 AGA
44 EURL C-7.4 Streptomycin, STR S >4 R > 16 AGA
44 EURL C-7.5 Erythromycin, ERY R >16 S = 1 AGA
44 EURL C-7.5 Tetracycline, TET R >128 S = 0.12 AGA
44 EURL C-7.6 Ciprofloxacin, CIP S >0.5 R = 16 AGA
44 EURL C-7.7 Erythromycin, ERY R >16 S = 1 AGA
44 EURL C-7.8 Ciprofloxacin, CIP S <0.5 R > 4 AGA
44 EURL C-7.8 Nalidixic acid, NAL S <16 R > 64 AGA
AGA Agar dilution
MIC Microbroth dilution
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Optional genotypic characterisation
Lab no. Strain Gene tested
Not 
detected Primer used 5’→3’ Primer used 3’→5’ PCR-method Reference
I EURL S-7.1 CTX M-15 Whole genome sequencing
I EURL S-7.1 OXA -30 Whole genome sequencing
I EURL S-7.1 TEM -1 Whole genome sequencing
I EURL S-7.2 CTX M-15 Whole genome sequencing
I EURL S-7.2 OXA -10 Whole genome sequencing
I EURL S-7.2 TEM -1 Whole genome sequencing
I EURL S-7.3 CTX M-9 Whole genome sequencing
I EURL S-7.3 TEM -1 Whole genome sequencing
I EURL S-7.6 ACC -1 Whole genome sequencing
III EURL S-7.1 CTX M-15 Published Carattoli et al. JCM 2008
III EURL S-7.1 OXA -31 Published Guerra et al. AAC 2000
III EURL S-7.1 TEM -1 Published Guerra et al. AAC 2001
III EURL S-7.1 ACC X Published Pérez-Perez JCM 2002
III EURL S-7.1 ACT X Provided by EURL-AR (Hasman)
III EURL S-7.1 CMY-2 X Published Zhao 2001
III EURL S-7.1 DHA X Published Pérez-Perez JCM 2002
III EURL S-7.1 FOX X Published Pérez-Perez JCM 2002
III EURL S-7.1 GES X Provided by EURL-AR (Hasman)
III EURL S-7.1 IMP X Published Dallene JAC 2010
III EURL S-7.1 KPC X Published Dallene JAC 2010
III EURL S-7.1 MOX X Published Pérez-Perez JCM 2002
III EURL S-7.1 NDM X Published Poirel DMID 2011
III EURL S-7.1 PER X Provided by EURL-AR (Hasman)
III EURL S-7.1 SHV X Published Weill JCM 2004
III EURL S-7.1 VEB X Provided by EURL-AR (Hasman)
III EURL S-7.1 VIM X Published Dallene JAC 2010
III EURL S-7.2 CTX M-15
III EURL S-7.2 OXA -31
III EURL S-7.2 TEM -1
III EURL S-7.2 ACC X
III EURL S-7.2 ACT X
III EURL S-7.2 CMY-2 X
III EURL S-7.2 DHA X
III EURL S-7.2 FOX X
III EURL S-7.2 GES X
III EURL S-7.2 IMP X
III EURL S-7.2 KPC X
III EURL S-7.2 MOX X
III EURL S-7.2 NDM X
III EURL S-7.2 PER X
III EURL S-7.2 SHV X
III EURL S-7.2 VEB X
III EURL S-7.2 VIM X
III EURL S-7.3 CTX M-9
III EURL S-7.3 TEM -1
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Lab no. Strain Gene tested
Not 
detected Primer used 5’→3’ Primer used 3’→5’ PCR-method Reference
III EURL S-7.3 ACC X
III EURL S-7.3 ACT X
III EURL S-7.3 CMY X
III EURL S-7.3 DHA X
III EURL S-7.3 FOX X
III EURL S-7.3 GES X
III EURL S-7.3 IMP X
III EURL S-7.3 KPC X
III EURL S-7.3 MOX X
III EURL S-7.3 NDM X
III EURL S-7.3 OXA X
III EURL S-7.3 PER X
III EURL S-7.3 SHV X
III EURL S-7.3 VEB X
III EURL S-7.3 VIM X
III EURL S-7.6 ACC -1
III EURL S-7.6 ACT X
III EURL S-7.6 CMY X
III EURL S-7.6 CTX X
III EURL S-7.6 DHA X
III EURL S-7.6 FOX X
III EURL S-7.6 GES X
III EURL S-7.6 IMP X
III EURL S-7.6 KPC X
III EURL S-7.6 MOX X
III EURL S-7.6 NDM X
III EURL S-7.6 OXA X
III EURL S-7.6 PER X
III EURL S-7.6 SHV X
III EURL S-7.6 TEM X
III EURL S-7.6 VEB X
III EURL S-7.6 VIM X
IV EURL S-7.1 CTX M-15 PCR (published) J Clin Microbiol 2008;46:103-8
IV EURL S-7.2 CTX M-15 PCR (published) J Clin Microbiol 2008;46:103-8
IV EURL S-7.3 CTX M-9 Emerg Infect Dis 2006;12:807-12
IV EURL S-7.6 ACC -1 PCR (published) J Clin Microbiol. 2002 Jun;40(6):2153-62
VI EURL S-7.1 CTX M-15 CCATGGTTAAAAAATCACTGCG CCGCTSRTTCTGGTSACYTAYTTYACCCA PCR (published) Pediatr Infect Dis J. 28:814-818.2009
VI EURL S-7.1 OXA -30 ATGAAAAACACAATACATATCAACTTCG AATGCGATCACCCATTCTAAAGACAC PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-7.1 TEM -1 GCGGAACCCCTATTTG CTCACTGATTAAGCATTGGT PCR (published) Antimicrobial Agents and Chemotherapy. 2009. 53:17
VI EURL S-7.1 CMY X GCACTTAGCCACCTATACGGCAG CCTGGCGCATTCTTGAAAAGC PCR (published) J. Antimicrob. Chemother. 2006 56:115-121
VI EURL S-7.1 SHV X TTATCTCCCTGTTAGCCACC CCGAGCGAAATCAGCAAATC PCR (published) FEMS Microbiol Lett. 1997. 152:163-7.
VI EURL S-7.2 CTX M-15 5'-CCATGGTTAAAAAATCACTGCG-3' CCGCTSRTTCTGGTSACYTAYTTYACCCA PCR (published) Pediatr Infect Dis J. 28:814-818.2009
VI EURL S-7.2 OXA -30 5'-ATGAAAAACACAATACATATCAACTTCG-3' AATGCGATCACCCATTCTAAAGACAC PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-7.2 TEM -1 5'-GCGGAACCCCTATTTG-3' CTCACTGATTAAGCATTGGT PCR (published) Antimicrobial Agents and Chemotherapy. 2009. 53:17
VI EURL S-7.2 CMY X 5'-GCACTTAGCCACCTATACGGCAG-3' CCTGGCGCATTCTTGAAAAGC PCR (published) J. Antimicrob. Chemother. 2006 56:115-121
VI EURL S-7.2 SHV X 5'-TTATCTCCCTGTTAGCCACC-3' CCGAGCGAAATCAGCAAATC PCR (published) FEMS Microbiol Lett. 1997. 152:163-7.
VI EURL S-7.3 CTX M-9 GTGACAAAGAGAGTGCAACGG GGCTTCAGCGGCGAGAATCAT PCR (published) J Antimicrob Chemother. 2005. 56:1107-10.
VI EURL S-7.3 TEM -1 GCGGAACCCCTATTTG CTCACTGATTAAGCATTGGT PCR (published) Antimicrobial Agents and Chemotherapy. 2009. 53:17
VI EURL S-7.3 CMY X GCACTTAGCCACCTATACGGCAG CCTGGCGCATTCTTGAAAAGC PCR (published) .J. Antimicrob. Chemother.2006 56:115-121
VI EURL S-7.3 OXA X ATGAAAAACACAATACATATCAACTTCG AATGCGATCACCCATTCTAAAGACAC PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64,
VI EURL S-7.3 SHV X TTATCTCCCTGTTAGCCACC CCGAGCGAAATCAGCAAATC PCR (published) FEMS Microbiol Lett. 1997. 152:163-7.
VII EURL S-7.1 CTX AAA AAT CAC TGC GYC AGT TC AGC TTA TTC ATC GCC ACG TT PCR (published) Woodford et al.2006
VII EURL S-7.1 OXA ACA CAA TAC ATA TCA ACT TCG C AGT GTG TTT AGA ATG GTG ATC PCR (published) Fang et al. 2006
VII EURL S-7.1 TEM CGC CGC ATA CAC TAT TCT CAG AAT GA ACG CTC ACC GGC TCC AGA TTT AT PCR (published) Fang et al. 2006
VII EURL S-7.2 CTX AAA AAT CAC TGC GYC AGT TC AGC TTA TTC ATC GCC ACG TT PCR (published) Woodford et al.2006
VII EURL S-7.2 OXA ACA CAA TAC ATA TCA ACT TCG C AGT GTG TTT AGA ATG GTG ATC PCR (published) Fang et al. 2006
VII EURL S-7.2 TEM CGC CGC ATA CAC TAT TCT CAG AAT GA ACG CTA ACC GGC TCC AGA TTT AT PCR (published) Fang et al. 2006
VII EURL S-7.3 CTX CAA AGA GAR TGC AAC GGA TG ATT GGA AAG CGT TCA TCA CC PCR (published) Woodford et al.2006
VII EURL S-7.3 TEM CGC CGC ATA CAC TAT TCT CAG AAT GA ACG CTC ACC GGC TCC AGA TTT AT PCR (published) Fang et al. 2006
VII EURL S-7.6 ACC AAC AGC CTC AGC AGC CGG TTA TTC GCC GCA ATC ATC CCT AGC PCR (published) Pérez-Perez and Hanson,2002
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Lab no. Strain Gene tested
Not 
detected Primer used 5’→3’ Primer used 3’→5’ PCR-method Reference
VIII EURL S-7.1 CTX
VIII EURL S-7.1 OXA
VIII EURL S-7.1 TEM
VIII EURL S-7.1 ACC X
VIII EURL S-7.1 ACT X
VIII EURL S-7.1 CMY X
VIII EURL S-7.1 DHA X
VIII EURL S-7.1 FOX X
VIII EURL S-7.1 MOX X
VIII EURL S-7.1 PER X
VIII EURL S-7.1 SHV X
VIII EURL S-7.2 CTX
VIII EURL S-7.2 OXA
VIII EURL S-7.2 TEM
VIII EURL S-7.2 ACC X
VIII EURL S-7.2 ACT X
VIII EURL S-7.2 CMY X
VIII EURL S-7.2 DHA X
VIII EURL S-7.2 FOX X
VIII EURL S-7.2 MOX X
VIII EURL S-7.2 PER X
VIII EURL S-7.2 SHV X
VIII EURL S-7.3 CTX
VIII EURL S-7.3 TEM
VIII EURL S-7.3 ACC X
VIII EURL S-7.3 ACT X
VIII EURL S-7.3 DHA X
VIII EURL S-7.3 FOX X
VIII EURL S-7.3 OXA X
VIII EURL S-7.3 PER X
VIII EURL S-7.3 SHV X
VIII EURL S-7.6 ACC
VIII EURL S-7.6 TEM
VIII EURL S-7.6 ACT X
VIII EURL S-7.6 CTX X
VIII EURL S-7.6 DHA X
VIII EURL S-7.6 FOX X
VIII EURL S-7.6 OXA X
VIII EURL S-7.6 PER X
VIII EURL S-7.6 SHV X
IX EURL S-7.1 CTX M-15 PCR (published)
IX EURL S-7.1 SHV
IX EURL S-7.1 TEM -1 PCR (published)
IX EURL S-7.2 CTX M-15
IX EURL S-7.2 TEM -1
IX EURL S-7.2 SHV X
IX EURL S-7.3 CTX M-9
IX EURL S-7.3 TEM -1
IX EURL S-7.3 SHV X
IX EURL S-7.6 CMY X
IX EURL S-7.6 CTX X
IX EURL S-7.6 SHV X
IX EURL S-7.6 TEM X
X EURL S-7.1 CTX M-15 TTAGGAARTGTGCCGCTGYA CGATATCGTTGGTGGTRCCAT PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-7.1 OXA GGCACCAGATTCAACTTTCAAG GACCCCAAGTTTCCTGTAAGTG PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-7.1 TEM -1 CATTTCCGTGTCGCCCTTATTC CGTTCATCCATAGTTGCCTGAC PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-7.2 CTX M-15 TTAGGAARTGTGCCGCTGYA CGATATCGTTGGTGGTRCCAT PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-7.2 OXA GGCACCAGATTCAACTTTCAAG GACCCCAAGTTTCCTGTAAGTG PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-7.2 TEM -1 CATTTCCGTGTCGCCCTTATTC CGTTCATCCATAGTTGCCTGAC PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-7.3 CTX M-9 TCAAGCCTGCCGATCTGGT TGATTCTCGCCGCTGAAG PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-7.6 ACC -1 CACCTCCAGCGACTTGTTAC GTTAGCCAGCATCACGATCC PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
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Lab no. Strain Gene tested
Not 
detected Primer used 5’→3’ Primer used 3’→5’ PCR-method Reference
XI EURL S-7.1 CTX M-1 PCR (published)
XI EURL S-7.2 CTX M-1
XI EURL S-7.3 CTX M-4 PCR (published)
XI EURL S-7.6 ACC
XII EURL S-7.1 ACC X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.1 CMY X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.1 DHA X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.1 FOX X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.1 MOX X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.2 ACC X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.2 CMY X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.2 DHA X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.2 FOX X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.2 MOX X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.3 ACC X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.3 CMY X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.3 DHA X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.3 FOX X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.3 MOX X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.6 ACC PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.6 CMY X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.6 DHA X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.6 FOX X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XII EURL S-7.6 MOX X PCR (published) Journal of Clin. Microbiology Jun 2002 p2153-2162
XIII EURL S-7.1 ACC X AACAGCCTCAGCAGCCGGTTA TTCGCCGCAATCATCCCTAGC PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.1 DHA X AACTTTCACAGGTGTGCTGGGT CCGTACGCATACTGGCTTTGC PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.1 FOX X AACATGGGGTATCAGGGAGATG CAAAGCGCGTAACCGGATTGG PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.1 MOX X GCTGCTCAA GGAGCACAGGAT CACATTGACATAGGTGTGGTGC PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.2 ACC X AACAGCCTCAGCAGCCGGTTA TTCGCCGCAATCATCCCTAGC PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.2 DHA X AACTTTCACAGGTGTGCTGGGT CCGTACGCATACTGGCTTTGC PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.2 FOX X AACATGGGGTATCAGGGAGATG CAAAGCGCGTAACCGGATTGG PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.2 MOX X GCTGCTCAA GGAGCACAGGAT CACATTGACATAGGTGTGGTGC PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.3 ACC X AACAGCCTCAGCAGCCGGTTA TTCGCCGCAATCATCCCTAGC PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.3 DHA X AACTTTCACAGGTGTGCTGGGT CCGTACGCATACTGGCTTTGC PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.3 FOX X AACATGGGGTATCAGGGAGATG CAAAGCGCGTAACCGGATTGG PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.3 MOX X GCTGCTCAA GGAGCACAGGAT CACATTGACATAGGTGTGGTGC PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.6 ACC AACAGCCTCAGCAGCCGGTTA TTCGCCGCAATCATCCCTAGC PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.6 DHA X AACTTTCACAGGTGTGCTGGGT CCGTACGCATACTGGCTTTGC PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.6 FOX X AACATGGGGTATCAGGGAGATG CAAAGCGCGTAACCGGATTGG PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
XIII EURL S-7.6 MOX X GCTGCTCAA GGAGCACAGGAT CACATTGACATAGGTGTGGTGC PCR (published) F. J. Perez-Perez et al., 2002, J.Clin.Microbiol
Legend: 
Fields shaded grey indicate that the gene was expected
Genes in bold were detected but not expected 
National Food Institute
Technical University of Denmark
Kemitorvet, 204
DK - 2800 Kgs Lyngby
Tel.   35 88  70 00
Fax   35 88  70 01
www.food.dtu.dk 
ISBN:  978-87-92763-80-8
